<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Intravenous immunoglobulin for the treatment of childhood encephalitis - Iro, MA - 2017 | Cochrane Library</title> <meta content="Intravenous immunoglobulin for the treatment of childhood encephalitis - Iro, MA - 2017 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011367.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Intravenous immunoglobulin for the treatment of childhood encephalitis - Iro, MA - 2017 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011367.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD011367.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Intravenous immunoglobulin for the treatment of childhood encephalitis" name="citation_title"/> <meta content="Mildred A Iro" name="citation_author"/> <meta content="University of Oxford and the NIHR Oxford Biomedical Research Centre" name="citation_author_institution"/> <meta content="mildred.iro@paediatrics.ox.ac.uk" name="citation_author_email"/> <meta content="Natalie G Martin" name="citation_author"/> <meta content="Christchurch School of Medicine, University of Otago" name="citation_author_institution"/> <meta content="Michael Absoud" name="citation_author"/> <meta content="Evelina London Children's Hospital, Guy's and St Thomas' Hospital, King's Health Partners" name="citation_author_institution"/> <meta content="Andrew J Pollard" name="citation_author"/> <meta content="Children's Hospital" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="10" name="citation_issue"/> <meta content="10.1002/14651858.CD011367.pub2" name="citation_doi"/> <meta content="2017" name="citation_date"/> <meta content="2017/10/02" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011367.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011367.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011367.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Bias; Disability Evaluation; Encephalitis, Japanese [therapy]; Encephalitis, Viral [*therapy]; Glasgow Coma Scale; Immunoglobulins, Intravenous [adverse effects, *therapeutic use]; Length of Stay; Placebos [therapeutic use]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011367.pub2&amp;doi=10.1002/14651858.CD011367.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011367.pub2&amp;doi=10.1002/14651858.CD011367.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011367.pub2&amp;doi=10.1002/14651858.CD011367.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011367.pub2&amp;doi=10.1002/14651858.CD011367.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011367.pub2&amp;doi=10.1002/14651858.CD011367.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011367.pub2&amp;doi=10.1002/14651858.CD011367.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011367.pub2&amp;doi=10.1002/14651858.CD011367.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011367.pub2&amp;doi=10.1002/14651858.CD011367.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011367.pub2&amp;doi=10.1002/14651858.CD011367.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011367.pub2&amp;doi=10.1002/14651858.CD011367.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011367.pub2&amp;doi=10.1002/14651858.CD011367.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011367.pub2&amp;doi=10.1002/14651858.CD011367.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011367.pub2&amp;doi=10.1002/14651858.CD011367.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011367.pub2&amp;doi=10.1002/14651858.CD011367.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011367.pub2&amp;doi=10.1002/14651858.CD011367.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011367.pub2&amp;doi=10.1002/14651858.CD011367.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011367.pub2&amp;doi=10.1002/14651858.CD011367.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011367.pub2&amp;doi=10.1002/14651858.CD011367.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011367.pub2&amp;doi=10.1002/14651858.CD011367.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011367.pub2&amp;doi=10.1002/14651858.CD011367.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011367.pub2&amp;doi=10.1002/14651858.CD011367.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011367.pub2&amp;doi=10.1002/14651858.CD011367.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011367.pub2&amp;doi=10.1002/14651858.CD011367.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="6nHUP32m";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD011367\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD011367\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011367\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011367\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","ms","hr","zh_HANS","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD011367.pub2",title:"Intravenous immunoglobulin for the treatment of childhood encephalitis",firstPublishedDate:"Oct 2, 2017 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Multiple Sclerosis and Rare Diseases of the CNS Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=6nHUP32m&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011367.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011367.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD011367.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD011367.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011367.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD011367.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011367.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD011367.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011367.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD011367.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD011367.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD011367.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD011367.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD011367.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>4005 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD011367.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011367.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011367.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011367.pub2/full#CD011367-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011367.pub2/full#CD011367-sec-0106"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011367.pub2/full#CD011367-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011367.pub2/full#CD011367-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011367.pub2/full#CD011367-sec-0034"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011367.pub2/full#CD011367-sec-0035"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011367.pub2/full#CD011367-sec-0068"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011367.pub2/full#CD011367-sec-0100"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD011367.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011367.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011367.pub2/appendices#CD011367-sec-0111"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011367.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011367.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD011367.pub2/media/CDSR/CD011367/table_n/CD011367StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD011367.pub2/media/CDSR/CD011367/table_n/CD011367StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011367.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011367.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011367.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011367.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011367.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD011367.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2017 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD011367.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Intravenous immunoglobulin for the treatment of childhood encephalitis</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011367.pub2/information#CD011367-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Mildred A Iro</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011367.pub2/information#CD011367-cr-0003">Natalie G Martin</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011367.pub2/information#CD011367-cr-0004">Michael Absoud</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011367.pub2/information#CD011367-cr-0005">Andrew J Pollard</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD011367.pub2/information/en#CD011367-sec-0122">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 02 October 2017 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD011367.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD011367.pub2">https://doi.org/10.1002/14651858.CD011367.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD011367-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011367-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011367-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011367-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011367-abs-0008">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD011367-abs-0001" lang="en"> <section id="CD011367-sec-0001"> <h3 class="title" id="CD011367-sec-0001">Background</h3> <p>Encephalitis is a syndrome of neurological dysfunction due to inflammation of the brain parenchyma, caused by an infection or an exaggerated host immune response, or both. Attenuation of brain inflammation through modulation of the immune response could improve patient outcomes. Biological agents such as immunoglobulin that have both anti‐inflammatory and immunomodulatory properties may therefore be useful as adjunctive therapies for people with encephalitis. </p> </section> <section id="CD011367-sec-0002"> <h3 class="title" id="CD011367-sec-0002">Objectives</h3> <p>To assess the efficacy and safety of intravenous immunoglobulin (IVIG) as add‐on treatment for children with encephalitis. </p> </section> <section id="CD011367-sec-0003"> <h3 class="title" id="CD011367-sec-0003">Search methods</h3> <p>The Cochrane Multiple Sclerosis and Rare Diseases of the CNS group's Information Specialist searched the following databases up to 30 September 2016: CENTRAL, MEDLINE, Embase, CINAHL, ClinicalTrials.gov, and the WHO ICTRP Search Portal. In addition, two review authors searched Science Citation Index Expanded (SCI‐EXPANDED) &amp; Conference Proceedings Citation Index ‐ Science (CPCI‐S) (Web of Science Core Collection, Thomson Reuters) (1945 to January 2016), Global Health Library (Virtual Health Library), and Database of Abstracts of Reviews of Effects (DARE). </p> </section> <section id="CD011367-sec-0004"> <h3 class="title" id="CD011367-sec-0004">Selection criteria</h3> <p>Randomised controlled trials (RCTs) comparing IVIG in addition to standard care versus standard care alone or placebo. </p> </section> <section id="CD011367-sec-0005"> <h3 class="title" id="CD011367-sec-0005">Data collection and analysis</h3> <p>Two review authors independently selected articles for inclusion, extracted relevant data, and assessed quality of trials. We resolved disagreements by discussion among the review authors. Where possible, we contacted authors of included studies for additional information. We presented results as risk ratios (RR) or mean differences (MD) with 95% confidence intervals (CI). </p> </section> <section id="CD011367-sec-0006"> <h3 class="title" id="CD011367-sec-0006">Main results</h3> <p>The search identified three RCTs with 138 participants. All three trials included only children with viral encephalitis, one of these included only children with Japanese encephalitis, a specific form of viral encephalitis. Only the trial of Japanese encephalitis (22 children) contributed to the primary outcome of this review and follow‐up in that study was for three to six months after hospital discharge. There was no follow‐up of participants in the other two studies. We identified one ongoing trial. </p> <p>For the primary outcomes, the results showed no significant difference between IVIG and placebo when used in the treatment of children with Japanese encephalitis: significant disability (RR 0.75, 95% CI 0.22 to 2.60; P = 0.65) and serious adverse events (RR 1.00, 95% CI 0.07 to 14.05; P = 1.00). </p> <p>For the secondary outcomes, the study of Japanese encephalitis showed no significant difference between IVIG and placebo when assessing significant disability at hospital discharge (RR 1.00, 95% CI 0.60 to 1.67). There was no significant difference (P = 0.53) in Glasgow Coma Score at discharge between IVIG (median score 14; range 3 to 15) and placebo (median 14 score; range 7 to 15) in the Japanese encephalitis study. The median length of hospital stay in the Japanese encephalitis study was similar for IVIG‐treated (median 13 days; range 9 to 21) and placebo‐treated (median 12 days; range 6 to 18) children (P = 0.59). </p> <p>Pooled analysis of the results of the other two studies resulted in a significantly lower mean length of hospital stay (MD ‐4.54 days, 95% CI ‐7.47 to ‐1.61; P = 0.002), time to resolution of fever (MD ‐0.97 days, 95% CI ‐1.25 to ‐0.69; P &lt; 0.00001), time to stop spasms (MD ‐1.49 days, 95% CI ‐1.97 to ‐1.01; P &lt; 0.00001), time to regain consciousness (MD ‐1.10 days, 95% CI ‐1.48 to ‐0.72; P &lt; 0.00001), and time to resolution of neuropathic symptoms (MD ‐3.20 days, 95% CI ‐3.34 to ‐3.06; P &lt; 0.00001) in favour of IVIG when compared with standard care. </p> <p>None of the included studies reported other outcomes of interest in this review including need for invasive ventilation, duration of invasive ventilation, cognitive impairment, poor adaptive functioning, quality of life, number of seizures, and new diagnosis of epilepsy. </p> <p>The quality of evidence was very low for all outcomes of this review.</p> </section> <section id="CD011367-sec-0007"> <h3 class="title" id="CD011367-sec-0007">Authors' conclusions</h3> <p>The findings suggest a clinical benefit of adjunctive IVIG treatment for children with viral encephalitis for some clinical measures (i.e. mean length of hospital stay, time (days) to stop spasms, time to regain consciousness, and time to resolution of neuropathic symptoms and fever. For children with Japanese encephalitis, IVIG had a similar effect to placebo when assessing significant disability and serious adverse events. </p> <p>Despite these findings, the risk of bias in the included studies and quality of the evidence make it impossible to reach any firm conclusions on the efficacy and safety of IVIG as add‐on treatment for children with encephalitis. Furthermore, the included studies involved only children with viral encephalitis, therefore findings of this review cannot be generalised to all forms of encephalitis. Future well‐designed RCTs are needed to assess the efficacy and safety of IVIG in the management of children with all forms of encephalitis. There is a need for internationally agreed core outcome measures for clinical trials in childhood encephalitis. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD011367-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011367-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD011367-abs-0004">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD011367-abs-0007">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011367-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD011367-abs-0006">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD011367-abs-0005">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011367-abs-0009">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD011367-abs-0003" lang="en"> <h3>An assessment of the effectiveness and safety of a treatment used for children with encephalitis </h3> <p><b>Background</b> </p> <p>At present, there is uncertainty among clinicians regarding the routine use of a treatment called intravenous immunoglobulin (IVIG) in the management of children with some forms of encephalitis (inflammation of the brain). This study is important because it is the first to evaluate through direct comparison whether adding IVIG to standard treatment has added beneficial effect in terms of clinical effectiveness and safety in the management of children with encephalitis. </p> <p><b>Study characteristics</b> </p> <p>We searched medical databases for studies in which neither participants nor researchers were told which treatment was given (called a randomised double‐blind trial). The effectiveness and safety of IVIG were considered in terms of the occurrence of significant disability at six months after hospital discharge and the proportion of children experiencing at least one serious side effect. </p> <p><b>Key results and quality of evidence</b> </p> <p>Up to 30 September 2016, only three studies comprising 138 children met the criteria to be included in this review. All three studies included only children with viral encephalitis. One study of Japanese encephalitis, a specific form of viral encephalitis, analysed both effectiveness and safety, and concluded that IVIG treatment had no additional beneficial effects when compared with placebo (pretend) treatment. The other two studies analysed other measurements, such as length of hospital stay, time to resolution of spasms, symptoms arising due to nerve damage, and time to regain consciousness and concluded that adding IVIG treatment was more effective than standard care alone when these outcomes were considered. The quality of the evidence was very low due to the small number of children and studies. </p> <p><b>Conclusions</b> </p> <p>The quality of evidence in the included studies was very low, making it impossible to draw any firm and definite conclusions on the clinical efficacy and safety of IVIG treatment for children with encephalitis. </p> <p>Furthermore, there was no information on funding while, for one study, the main authors' group was affiliated to the funding body: this is a well‐known potential source of conflict of interest and thus of bias. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD011367-sec-0106" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD011367-sec-0106"></div> <h3 class="title" id="CD011367-sec-0107">Implications for practice</h3> <section id="CD011367-sec-0107"> <p>Evidence of very low quality suggests a beneficial effect of intravenous immunoglobulin (IVIG) in reducing length of hospital stay, time to resolution of fever, spasms, neuropathic symptoms, and time to regain consciousness and a lack of benefit in terms of mortality and significant disability. However, due to the limitations of the included studies, we are unable to draw definite conclusions from the presented evidence on the safety and efficacy of IVIG treatment for childhood encephalitis. </p> </section> <h3 class="title" id="CD011367-sec-0108">Implications for research</h3> <section id="CD011367-sec-0108"> <p>Outcomes for childhood encephalitis are poor despite currently available treatment, which highlights the need to identify other treatment options. There is increasing evidence of a beneficial role of IVIG in the treatment of encephalitis, yet robust trials assessing this are lacking. Therefore, well‐designed randomised controlled trials are needed to investigate the role of IVIG in all forms of encephalitis and to provide evidence to inform clinical practice on the management of children with encephalitis. Future trials should include a clear objective definition of encephalitis, which is aligned with the published consensus definition for encephalitis (<a href="./references#CD011367-bbs2-0086" title="VenkatesanA , TunkelAR , BlochKC , LauringAS , SejvarJ , BitnunA , et al. Case definitions, diagnostic algorithms, and priorities in encephalitis: consensus statement of the international encephalitis consortium. Clinical Infectious Diseases2013;57(8):1114‐28. [PUBMED: PMID 23861361] ">Venkatesan 2013</a>) to ensure a homogenous population. There remains the need for internationally agreed core outcome measures for clinical trials in childhood encephalitis. For future trials, consideration should be given to clinically relevant outcomes including disability, cognitive functioning, and adaptive skills and, where possible, these should be assessed using validated tools. Long‐term follow‐up (beyond the hospitalisation period) needs to be assessed. Consideration should be given to a large sample size with statistical power to detect clinically significant differences in these outcomes and longer‐term follow‐up. Results of an ongoing trial will be crucial in addressing this key question (<a href="./references#CD011367-bbs2-0013" title="NCT02308982 . Investigating the role of early intravenous immunoglobulin treatment for children with encephalitis [A phase III multi‐centre randomised, double blind, placebo controlled trial to assess the role of intravenous immunoglobulin in the management of children with encephalitis]. clinicaltrials.gov/ct2/show/record/NCT02308982 Date first received; 1 December 2014. ">NCT02308982</a>). </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD011367-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD011367-sec-0022"></div> <div class="table" id="CD011367-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Intravenous immunoglobulin with or without standard care compared with standard care alone or placebo for children with acute encephalitis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Intravenous immunoglobulin ± standard care compared with standard care alone or placebo for children with acute encephalitis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> children with acute encephalitis </p> <p><b>Settings:</b> secondary and tertiary care </p> <p><b>Intervention:</b> intravenous immunoglobulin </p> <p><b>Comparison:</b> placebo or standard care </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk (control)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk (intervention)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Standard care or placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>IVIG (± standard care)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Significant disability</b> assessed using Liverpool Outcome Score </p> <p>RR (M‐H, random‐effects analysis, 95% CI)</p> <p>Follow‐up: 3‐6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>364 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>273 per 1000</b> <br/> (80 to 945) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.75</b> </p> <p>(0.22 to 2.60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22<br/> (1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b,c,d,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear risk of detection bias and high risk of publication bias. Small sample size. Study not powered on primary outcome. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>≥ 1 serious adverse event</b> </p> <p>RR (M‐H, random‐effects analysis, 95% CI)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>91 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>91 per 1000</b> <br/> (6 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.00</b> </p> <p>(0.07 to 14.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22<br/> (1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b,c,d,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear risk of detection bias and high risk of publication bias. Small sample size. Study not powered on primary outcome. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Length of hospital stay</b> </p> <p>(MD, random‐effects analysis, 95% CI)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean length of hospital stay was 13.26</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 4.54 lower (7.47 to 1.61 lower)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>116<br/> (2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>d,f,g,h,i</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear risk of selection bias in 1 study contributing to this outcome assessment. Unclear risk of allocation concealment, performance and detection bias in both studies. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>IVIG:</b> intravenous immunoglobulin; <b>M‐H:</b> Mantel‐Haenszel; <b>MD</b> : mean difference; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Unclear risk of detection bias. </p> <p><sup>b</sup>Conflicts of interest could not be excluded. </p> <p><sup>c</sup>Study of Japanese encephalitis, therefore, results not generalisable to other forms of encephalitis. </p> <p><sup>d</sup>Small sample size in studies contributing to this outcome. </p> <p><sup>e</sup>Some predefined outcomes were not reported. </p> <p><sup>f</sup>Unclear risk of performance and detection bias in both studies contributing to this outcome. </p> <p><sup>g</sup>Unclear risk of selection bias in one study contributing to this outcome assessment. </p> <p><sup>h</sup>High proportion of variation in point estimates. </p> <p><sup>i</sup>Both studies included only children with viral encephalitis, therefore, results not generalisable to other forms of encephalitis. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD011367-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD011367-sec-0023"></div> <section id="CD011367-sec-0024"> <h3 class="title" id="CD011367-sec-0024">Description of the condition</h3> <p>Encephalitis is a syndrome of neurological dysfunction that results from inflammation of the brain parenchyma. The worldwide annual incidence ranges from 3.5 to 7.4 per 100,000, rising to 16 per 100,000 in children, with the highest incidence in infants under one year of age (<a href="./references#CD011367-bbs2-0080" title="ThompsonC , KneenR , RiordanA , KellyD , PollardA J . Encephalitis in children. Archives of Disease in Childhood2012;97:150‐61. [PUBMED: PMID: 21715390] ">Thompson 2012</a>). In England, the incidence of childhood encephalitis is 4.02 per 100,000 per year (<a href="./references#CD011367-bbs2-0048" title="IroMA , SadaranganiM , GoldacreR , NicklessA , PollardAJ , GoldacreMJ . 30‐year trends in admission rates for encephalitis in children in England and effect of improved diagnostics and measles‐mumps‐rubella vaccination: a population‐based observational study. Lancet Infectious Diseases2017;17(4):422‐30. ">Iro 2017</a>). Encephalitis could result from an infection of the brain (infectious encephalitis) or from autoantibodies that affect the brain (immune‐mediated encephalitis), or both (<a href="./references#CD011367-bbs2-0091" title="ZulianiL , GrausF , GiomettoB , BienC , VincentA . Central nervous system neuronal surface antibody associated syndromes: review and guidelines for recognition. Journal of Neurology, Neurosurgery, and Psychiatry2012;83:638‐45. ">Zuliani 2012</a>). </p> <p>Infections have been considered the major cause of encephalitis and more than 100 different causative pathogens have been recognised. Viruses are the most common pathogens known to cause encephalitis. However, a host of other pathogens including bacteria and protozoa have also been implicated. </p> <p>Immune‐mediated disorders, such as acute disseminated encephalomyelitis, are now recognised to contribute to a significant proportion of cases where no infective cause is identified (<a href="./references#CD011367-bbs2-0040" title="GranerodJ , AmbroseHE , DaviesNW , ClewleyJP , WalshAL , MorganD , et al. Causes of encephalitis and differences in their clinical presentations in England: a multicentre, population‐based prospective study. Lancet Infectious Diseases2010;10(12):835‐44. [PUBMED: PMID: 20952256] ">Granerod 2010</a>). More recently, several well‐characterised immunological syndromes that are mediated by antibodies against central nervous system surface proteins such as the N‐methyl‐D‐aspartate receptor and the voltage‐gated potassium channel‐complex and its associated proteins, have been identified in people with encephalitis (<a href="./references#CD011367-bbs2-0041" title="HacohenY , WrightS , WatersP , AgrawalS , CarrL , CrossH , et al. Paediatric autoimmune encephalopathies: clinical features, laboratory investigations and outcomes in patients with or without antibodies to known central nervous system autoantigens. Journal of Neurology, Neurosurgery, and Psychiatry2013;84(7):748‐55. [PUBMED: 23175854] ">Hacohen 2013</a>; <a href="./references#CD011367-bbs2-0042" title="HacohenY , DeivaK , PettingillP , WatersP , SiddiquiA , ChretienP , et al. N‐methyl‐D‐aspartate receptor antibodies in post‐herpes simplex virus encephalitis neurological relapse. Movement Disorders2014;29:90‐6. ">Hacohen 2014</a>), and these account for 4% and 7% of overall cases (<a href="./references#CD011367-bbs2-0040" title="GranerodJ , AmbroseHE , DaviesNW , ClewleyJP , WalshAL , MorganD , et al. Causes of encephalitis and differences in their clinical presentations in England: a multicentre, population‐based prospective study. Lancet Infectious Diseases2010;10(12):835‐44. [PUBMED: PMID: 20952256] ">Granerod 2010</a>). However, despite routine investigations, no aetiology is found in up to 60% of cases of encephalitis (<a href="./references#CD011367-bbs2-0026" title="DavisonKL , CrowcroftNS , RamsayME , BrownDW , AndrewsNJ . Viral encephalitis in England, 1989‐1998: what did we miss?. Emerging Infectious Diseases2003;9(2):234‐40. [PUBMED: PMID 12603996] ">Davison 2003</a>; <a href="./references#CD011367-bbs2-0040" title="GranerodJ , AmbroseHE , DaviesNW , ClewleyJP , WalshAL , MorganD , et al. Causes of encephalitis and differences in their clinical presentations in England: a multicentre, population‐based prospective study. Lancet Infectious Diseases2010;10(12):835‐44. [PUBMED: PMID: 20952256] ">Granerod 2010</a>). </p> <p>There is a high rate of mortality and morbidity from encephalitis, despite current standard of care. An exaggerated host immune response has been implicated in the pathogenesis of encephalitis and this has been shown to play a part in the disease pathogenesis (<a href="./references#CD011367-bbs2-0022" title="Cervantes‐BarragánL , FirnerS , BechmannI , WaismanA , LahlK , SparwasserT , et al. Regulatory T cells selectively preserve immune privilege of self‐antigens during viral central nervous system infection. Journal of Immunology (Baltimore, Md. : 1950)2012;188(8):3678‐85. [PUBMED: PMID: 22407917] ">Cervantes‐Barragán 2012</a>; <a href="./references#CD011367-bbs2-0027" title="deAquinoMT , PuntambekarSS , SavarinC , BergmannCC , PharesTW , HintonDR , et al. Role of CD25(+) CD4(+) T cells in acute and persistent coronavirus infection of the central nervous system. Virology2013;447:112‐20. ">de Aquino 2013</a>; <a href="./references#CD011367-bbs2-0059" title="LundbergP , RamakrishnaC , BrownJ , TyszkaJ , HamamuraM , HintonD , et al. The immune response to herpes simplex virus type 1 infection in susceptible mice is a major cause of central nervous system pathology resulting in fatal encephalitis. Journal of Virology2008;82:7078‐88. [PUBMED: PMCID: PMC2446972; PUBMED: PMID: 18480436] ">Lundberg 2008</a>; <a href="./references#CD011367-bbs2-0067" title="RamakrishnaC , OpenshawH , CantinEM . The case for immunomodulatory approaches in treating HSV encephalitis. Future Virology2013;8(3):259‐72. ">Ramakrishna 2013</a>). </p> <p>While a mortality rate of up to 20% has been reported (<a href="./references#CD011367-bbs2-0040" title="GranerodJ , AmbroseHE , DaviesNW , ClewleyJP , WalshAL , MorganD , et al. Causes of encephalitis and differences in their clinical presentations in England: a multicentre, population‐based prospective study. Lancet Infectious Diseases2010;10(12):835‐44. [PUBMED: PMID: 20952256] ">Granerod 2010</a>; <a href="./references#CD011367-bbs2-0067" title="RamakrishnaC , OpenshawH , CantinEM . The case for immunomodulatory approaches in treating HSV encephalitis. Future Virology2013;8(3):259‐72. ">Ramakrishna 2013</a>), incomplete recovery after childhood encephalitis is common with persisting symptoms in up to 60% of affected children (<a href="./references#CD011367-bbs2-0015" title="AygunA , KabakusN , CelikI , TurgutM , YoldasT , GökU , et al. Long term neurological outcome of acute encephalitis. Journal of Tropical Pediatrics2001;47(4):243‐7. [PUBMED: PMID 111523767] ">Aygun 2001</a>; <a href="./references#CD011367-bbs2-0034" title="FowlerA , StödbergT , ErikssonM , WickströmR . Long‐term outcomes of acute encephalitis in childhood. Pediatrics2010;126(4):828‐35. [PUBMED: PMID 20876179] ">Fowler 2010</a>). One 12‐year prospective study of children with herpes simplex virus encephalitis demonstrated that neurological sequelae occurred in 63% of cases, including seizures in 44% and developmental delay in 25% (<a href="./references#CD011367-bbs2-0035" title="FowlerA , StödbergT , ErikssonM , WickströmR . Childhood encephalitis in Sweden: etiology, clinical presentation and outcome. European Journal of Paediatric Neurology: EJPN2008;12:484‐90. ">Fowler 2008</a>). Long‐term complications such as severe physical impairment and behavioural, psychosocial, and educational difficulties have also been reported (<a href="./references#CD011367-bbs2-0029" title="DowellE , EastonA , SolomonT . The consequences of encephalitis. Report of a Postal Survey (Year 2000 survey) carried out by the Encephalitis Support Group. www.encephalitis.info/images/iPdf/Research2/CONSEQUENCES1.pdf (accessed 10 April 2014). ">Dowell 2000</a>). </p> <p>Encephalitis imposes a substantial economic and healthcare resource burden. Health, social, and economic costs are also extended where families are left bereaved or with a child who has sustained disability. One 12‐year US review reported an encephalitis‐associated hospitalisation rate of 6.9 per 100,000 people. The death rate in the same study was 5.8% of all hospitalisations (<a href="./references#CD011367-bbs2-0087" title="VoraNM , HolmanRC , MehalJM , SteinerCA , BlantonJ , SejvarJ . Burden of encephalitis‐associated hospitalizations in the United States, 1998‐2010. Neurology2014;82(5):443‐51. [PUBMED: PMID: 24384647] ">Vora 2014</a>). In one ten year review of encephalitis admissions to paediatric intensive care unit (ICU) in the England and Wales, 80% of admitted children required invasive ventilation, 19% required cardiovascular support and 6% required renal dialysis and the mean length of stay on ICU was 4.6 days (<a href="./references#CD011367-bbs2-0083" title="UK Trialists. Individual patient data (as supplied 30 April 2013). Data on File. ">UK Trialists</a>). One US study reported approximately 19,000 hospitalisations (7.3 hospitalisations per 100,000 population) and 230,000 hospital days from encephalitis over a 10‐year period, with an estimated cost from encephalitis‐associated hospitalisations of USD28,000 leading to an annual national cost of USD650 million (<a href="./references#CD011367-bbs2-0052" title="KhetsurianiN , HolmanC , AndersonL . Burden of encephalitis‐associated hospitalizations in the United States, 1988‐1997. Clinical Infectious Diseases2002;35(2):175‐82. [PUBMED: PMID: 12087524] ">Khetsuriani 2002</a>). </p> <p>Given this huge burden from encephalitis despite current standard of care, there is the need to identify other adjunctive treatment option that could be used in the management of children with encephalitis. </p> <p>Irrespective of aetiology, the underlying pathogenesis in encephalitis is brain inflammation. The degree of brain inflammation seen in some forms of encephalitis correlates with clinical outcomes (<a href="./references#CD011367-bbs2-0067" title="RamakrishnaC , OpenshawH , CantinEM . The case for immunomodulatory approaches in treating HSV encephalitis. Future Virology2013;8(3):259‐72. ">Ramakrishna 2013</a>). Attenuation of such inflammation either as a direct effect or through modulation of the immune response may therefore be key to improving clinical outcomes. Biological agents that possess anti‐inflammatory or immunomodulatory (or both) properties may therefore be useful as adjunctive therapies and could improve outcomes (<a href="./references#CD011367-bbs2-0067" title="RamakrishnaC , OpenshawH , CantinEM . The case for immunomodulatory approaches in treating HSV encephalitis. Future Virology2013;8(3):259‐72. ">Ramakrishna 2013</a>; <a href="./references#CD011367-bbs2-0072" title="RozenbergF . Acute viral encephalitis. Handbook of Clinical Neurology / Edited by P.J. Vinken and G.W. Bruyn2013;112:1171‐81. ">Rozenberg 2013</a>). Intravenous immunoglobulin (IVIG) is one such biological agent. </p> </section> <section id="CD011367-sec-0025"> <h3 class="title" id="CD011367-sec-0025">Description of the intervention</h3> <p>The aim of this review was to assess the role of add‐on IVIG in the treatment of children with all forms of acute encephalitis. Intravenous aciclovir is used as first‐line treatment for children with infective encephalitis. In autoimmune encephalitis, corticosteroid therapy is sometimes used. Therefore, we considered both treatments in this review. Plasmapheresis is not universally available and was not considered in this review, likewise the use of experimental therapies. </p> <section id="CD011367-sec-0026"> <h4 class="title">Intravenous immunoglobulin</h4> <p>IVIG is a blood product made from pooled collections of human plasma collected from thousands of blood donors. It comes as a ready‐to‐use liquid formulation for intravenous administration. It has a half‐life of three to four weeks. IVIG is being used increasingly in the management of a wide range of neurological conditions and its efficacy has been established in a few of these (<a href="./references#CD011367-bbs2-0046" title="HughesRA , DalakasMC , CornblathDR , LatovN , WekslerME , RelkinN . Clinical applications of intravenous immunoglobulins in neurology. Clinical and Experimental Immunology2009;158(Suppl 1):34‐42. [PUBMED: PMID: 19883422] ">Hughes 2009</a>). Licensed indications include as replacement therapy for people with primary and secondary antibody deficiency states, Kawasaki disease, haematological conditions (idiopathic immune thrombocytopenic purpura, B‐cell chronic lymphocytic leukaemia), and neurological conditions (myasthenia gravis, multifocal motor neuropathy, Guillain‐Barré syndrome, and chronic demyelinating polyneuropathy) (<a href="./references#CD011367-bbs2-0033" title="USFood , DrugAdministration . Immune globulin intravenous (IGIV) indications. Page last updated: 6 October 2013. www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/ucm133691.htm (accessed 15 May 2014). ">FDA 2013</a>). IVIG is sometimes also used off‐label for the treatment of children with encephalitis. </p> <p>The dose of IVIG for each indication varies. For primary and secondary antibody deficiency states, the starting dose is between 0.4 g/kg and 0.6 g/kg of bodyweight and needs to be adjusted based on clinical outcome. For neurological diseases, two doses of 2 g/kg of bodyweight over five days and given six weeks apart. For haematological conditions, a dose of 0.8 g/kg to 1 g/kg is used. </p> <p>IVIG treatment is safe; however, adverse events such as chills, headache, fever, vomiting, allergic reaction, nausea, arthralgia, low blood pressure, and low back pain may occur. Rarely, sudden fall in blood pressure, anaphylactic shock, and thromboembolic reactions could occur. Cases of reversible aseptic meningitis and isolated cases of haemolytic anaemia have been observed as well as acute renal failure. Since IVIG is a blood product, there is the risk of transmission of infectious agents such as HIV and viral hepatitis by contaminated products (<a href="./references#CD011367-bbs2-0058" title="LooneyRJ , HugginsJ . Use of intravenous immunoglobulin G (IVIG). Best Practice &amp; Research. Clinical Haematology2006;19:3‐25. ">Looney 2006</a>). </p> </section> <section id="CD011367-sec-0027"> <h4 class="title">Aciclovir</h4> <p>Aciclovir is widely used in the treatment of herpesvirus infections, particularly herpes simplex and varicella‐zoster virus. It is a synthetic nucleoside analogue with in vitro and in vivo inhibitory activity against herpes simplex virus types 1 and 2 as well as varicella‐zoster virus (<a href="./references#CD011367-bbs2-0030" title="ElionGB . The biochemistry and mechanism of action of acyclovir. Journal of Antimicrobial Chemotherapy1983;12 Suppl B:9‐17. ">Elion 1983</a>). Aciclovir is available in oral, topical, and intravenous forms. It is poorly water soluble and has poor oral bioavailability hence intravenous administration is necessary if high concentrations are required, such as in serious infections. The intravenous form is used in the treatment of herpes simplex and varicella‐zoster virus encephalitis and the dose is based on weight and varies with age: </p> <p> <ul id="CD011367-list-0001"> <li> <p>neonate (20 mg/kg);</p> </li> <li> <p>child one to three months (10 mg/kg to 20 mg/kg);</p> </li> <li> <p>child three months to 12 years (500 mg/m<sup>2</sup> every eight hours); </p> </li> <li> <p>child 12 years to 18 years (10 mg/kg every eight hours).</p> </li> </ul> </p> <p>Duration of treatment for encephalitis is 14 to 21 days (<a href="./references#CD011367-bbs2-0020" title="British National Formulary Publications. British National Formulary for Children (BNF for Children). Chapter 5.3.2: Herpesvirus infections; page 326. London (UK): British Medical Association, the Royal Pharmaceutical Society, the Royal College of Paediatrics and Child Health, the Neonatal and Paediatric Pharmacists Group, 2014‐2015. ">BNF Publications</a>). </p> <p>Adverse effects such as nausea, vomiting, diarrhoea, abdominal pain, hepatitis, and renal dysfunction have been reported with aciclovir use. Interactions have also been reported with ciclosporin (increased risk of toxicity), mycophenolate (increased plasma concentration of aciclovir and inactive metabolite of mycophenolate), probenecid (reduced excretion of aciclovir and increased plasma concentration), tacrolimus (increased risk of nephrotoxicity), and theophylline (increase plasma concentration of theophylline) (<a href="./references#CD011367-bbs2-0020" title="British National Formulary Publications. British National Formulary for Children (BNF for Children). Chapter 5.3.2: Herpesvirus infections; page 326. London (UK): British Medical Association, the Royal Pharmaceutical Society, the Royal College of Paediatrics and Child Health, the Neonatal and Paediatric Pharmacists Group, 2014‐2015. ">BNF Publications</a>). </p> </section> <section id="CD011367-sec-0028"> <h4 class="title">Corticosteroids</h4> <p>The role of corticosteroid in the treatment of encephalitis is not yet established. Although not routinely used in herpes simplex virus encephalitis (HSVE), corticosteroids are often used in people with HSVE with marked cerebral oedema, brain shift, or raised intracranial pressure. Information from experimental animal research (<a href="./references#CD011367-bbs2-0073" title="SellnerJ , DvorakF , ZhouY , HaasJ , KehmR , WildemannB , et al. Acute and long‐term alteration of chemokine mRNA expression after anti‐viral and anti‐inflammatory treatment in herpes simplex virus encephalitis. Neuroscience Letters2005;374:197‐202. ">Sellner 2005</a>; <a href="./references#CD011367-bbs2-0079" title="ThompsonKA , BlessingW , WesselinghSL . Herpes simplex replication and dissemination is not increased by corticosteroid treatment in a rat model of focal herpes encephalitis. Journal of Neurovirology2000;6:25‐32. ">Thompson 2000</a>), and from clinical observations (<a href="./references#CD011367-bbs2-0049" title="KameiS , SekizawaT , ShiotaH , MizutaniT , ItoyamaY , TakasuT , et al. Evaluation of combination therapy using aciclovir and corticosteroid in adult patients with herpes simplex virus encephalitis. Journal of Neurology, Neurosurgery, and Psychiatry2005;76:1544‐9. ">Kamei 2005</a>; <a href="./references#CD011367-bbs2-0057" title="LizarragaKJ , AlexandreLC , Ramos‐EstebanezC , MerendaA . Are steroids a beneficial adjunctive therapy in the immunosuppressed patient with herpes simplex virus encephalitis?. Case Reports in Neurology2013;5:52‐5. ">Lizarraga 2013</a>; <a href="./references#CD011367-bbs2-0068" title="Ramos‐EstebanezC , LizarragaKJ , MerendaA . A systematic review on the role of adjunctive corticosteroids in herpes simplex virus encephalitis: is timing critical for safety and efficacy?. Antiviral Therapy2014;19:133‐9. ">Ramos‐Estebanez 2014</a>), indicate a substantial benefit in outcomes for people with HSVE treated with adjuvant dexamethasone. Corticosteroids are potent anti‐inflammatory agents. Their clinical use along with antiviral therapy has been advocated in people with HSVE and cerebral oedema where they reduce brain swelling. Results of a prospective randomised controlled trial (RCT) on the use of adjunctive corticosteroid therapy in HSVE are awaited (<a href="./references#CD011367-bbs2-0062" title="Martinez‐TorresF , MenonS , PritschM , VictorN , JenetzkyE , JensenK , et al. Protocol for German trial of Acyclovir and Corticosteroids in Herpes‐simplex‐virus‐Encephalitis (GACHE): a multicenter, multinational, randomized, double‐blind, placebo‐controlled German, Austrian and Dutch trial [ISRCTN45122933]. BMC Neurology2008;8:40. ">Martinez‐Torres 2008</a>). </p> </section> </section> <section id="CD011367-sec-0029"> <h3 class="title" id="CD011367-sec-0029">How the intervention might work</h3> <section id="CD011367-sec-0030"> <h4 class="title">Intravenous immunoglobulin</h4> <p>IVIG has multiple actions which may operate in concert with each other. For a particular disease, there may be one predominant mechanism of action depending on the underlying disease pathogenesis. The most relevant actions of IVIG include the following: </p> <p> <ul id="CD011367-list-0002"> <li> <p>inhibition of complement binding and prevention of membrane attack complex formation (<a href="./references#CD011367-bbs2-0016" title="BastaM , IllaI , DalakasM C . Increased in vitro uptake of the complement C3b in the serum of patients with Guillain‐Barré syndrome, myasthenia gravis and dermatomyositis. Journal of Neuroimmunology1996;71:227‐9. ">Basta 1996</a>; <a href="./references#CD011367-bbs2-0017" title="BastaM , VanGoorF , LuccioliS , BillingsEM , VortmeyerAO , BaranyiL , et al. F(ab)'2‐mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins. Nature Medicine2003;9(4):431‐8. ">Basta 2003</a>; <a href="./references#CD011367-bbs2-0060" title="LutzHU , StammlerP , JelezarovaE , NaterM , SpäthPJ . High doses of immunoglobulin G attenuate immune aggregate‐mediated complement activation by enhancing physiologic cleavage of C3b in C3bn‐IgG complexes. Blood1996;88:184‐93. [PUBMED: PMID: 8704173] ">Lutz 1996</a>; <a href="./references#CD011367-bbs2-0066" title="MollnesTE , HøgåsenK , HoaasBF , MichaelsenTE , GarredP , HarboeM . Inhibition of complement‐mediated red cell lysis by immunoglobulins is dependent on the IG isotype and its C1 binding properties. Scandinavian Journal of Immunology1995;41:449‐56. [PUBMED: PMID:7725063] ">Mollnes 1995</a>); </p> </li> <li> <p>neutralisation of certain pathogenic cytokines (<a href="./references#CD011367-bbs2-0023" title="CrowAR , SongS , SempleJW , FreedmanJ , LazarusAH . A role for IL‐1 receptor antagonist or other cytokines in the acute therapeutic effects of IVIg?. Blood2007;109:155‐8. ">Crow 2007</a>; <a href="./references#CD011367-bbs2-0077" title="StangelM , SchumacherHC , RuprechtK , BoegnerF , MarxP . Immunoglobulins for intravenous use inhibit TNF alpha cytotoxicity in vitro. Immunological Investigations1997;26:569‐78. ">Stangel 1997</a>); </p> </li> <li> <p>regulation of autoantibodies or cytokines by anti‐idiotypic or anticytokine antibodies (<a href="./references#CD011367-bbs2-0028" title="DietrichG , KazatchkineMD . Normal immunoglobulin G (IgG) for therapeutic use (intravenous Ig) contain antiidiotypic specificities against an immunodominant, disease‐associated, cross‐reactive idiotype of human anti‐thyroglobulin autoantibodies. Journal of Clinical Investigation1990;85:620‐5. ">Dietrich 1990</a>; <a href="./references#CD011367-bbs2-0071" title="RossiF , SultanY , KazatchkineMD . Anti‐idiotypes against autoantibodies and alloantibodies to VIII:C (anti‐haemophilic factor) are present in therapeutic polyspecific normal immunoglobulins. Clinical and Experimental Immunology1988;74:311‐6. ">Rossi 1988</a>); </p> </li> <li> <p>blockade of Fc gamma receptors on macrophages (<a href="./references#CD011367-bbs2-0025" title="DalakasMC . The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence‐based indications and safety profile. Pharmacology &amp; Therapeutics2004;102:177‐93. ">Dalakas 2004</a>; <a href="./references#CD011367-bbs2-0050" title="KazatchkineMD , KaveriSV . Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. New England Journal of Medicine2001;345:747‐55. ">Kazatchkine 2001</a>); </p> </li> <li> <p>modulation of T‐cell function and antigen recognition (<a href="./references#CD011367-bbs2-0021" title="CaramelloP , CantaF , BalbianoR , LipaniF , AriaudoS , DeAgostiniM , et al. Role of intravenous immunoglobulin administration in Japanese encephalitis. Clinical Infectious Diseases2006;43(12):1620‐1. [PUBMED: PMID 17109300] ">Caramello 2006</a>; <a href="http://Dalakas, M.C., Mechanism of action of intravenous immunoglobulin and therapeutic considerations in the treatment of autoimmune neurologic diseases. Neurology, 1998. 51(6 Suppl 5): p. S2-8" target="_blank">Dalakas 1998</a>; <a href="./references#CD011367-bbs2-0067" title="RamakrishnaC , OpenshawH , CantinEM . The case for immunomodulatory approaches in treating HSV encephalitis. Future Virology2013;8(3):259‐72. ">Ramakrishna 2013</a>; <a href="./references#CD011367-bbs2-0078" title="Tha‐InT , BayryJ , MetselaarHJ , KaveriSV , KwekkeboomJ . Modulation of the cellular immune system by intravenous immunoglobulin. Trends in Immunology2008;29(12):608‐15. [PUBMED: PMID: 18926775] ">Tha‐In 2008</a>; <a href="./references#CD011367-bbs2-0082" title="TrinathJ , HegdeP , SharmaM , MaddurMS , RabinM , VallatJM , et al. Intravenous immunoglobulin expands regulatory T cells via induction of cyclooxygenase‐2‐dependent prostaglandin E2 in human dendritic cells. Blood2013;122(8):1419‐27. [PUBMED: PMID: 23847198] ">Trinath 2013</a>). </p> </li> </ul> </p> <p>Additional actions include the effect of IVIG on superantigens and enhancement of remyelination (<a href="./references#CD011367-bbs2-0024" title="DalakasM . Mechanism of action of intravenous immunoglobulin and therapeutic considerations in the treatment of autoimmune neurologic diseases. Neurology1998;51(6 Suppl 5):2‐8. [PUBMED: PMID 9851723] ">Dalakas 1998</a>). Antiviral functions of IVIG and its potential to inhibit viral infection has been demonstrated in vitro (<a href="./references#CD011367-bbs2-0036" title="FrenzelK , GanepolaS , MichelD , ThielE , KrügerDH , UharekL , et al. Antiviral function and efficacy of polyvalent immunoglobulin products against CMV isolates in different human cell lines. Medical Microbiology and Immunology2012;201:277‐86. ">Frenzel 2012</a>; <a href="./references#CD011367-bbs2-0053" title="KishimotoC , HiraokaY , TakadaH . Effects of immunoglobulin upon murine myocarditis caused by influenza A virus: superiority of intact type to F(ab')2 type. Journal of Cardiovascular Pharmacology2004;43(1):61‐7. ">Kishimoto 2004</a>; <a href="./references#CD011367-bbs2-0054" title="KrauseI , WuR , ShererY , PatanikM , PeterJ , ShoenfeldY . In vitro antiviral and antibacterial activity of commercial intravenous immunoglobulin preparations, a potential role for adjuvant intravenous immunoglobulin therapy in infectious diseases. Transfusion Medicine (Oxford, England)2002;12:133‐9. ">Krause 2002</a>). </p> </section> <section id="CD011367-sec-0031"> <h4 class="title">Aciclovir</h4> <p>The inhibitory activity of aciclovir is highly selective due to its affinity for the enzyme thymidine kinase encoded by herpes simplex and varicella‐zoster virus. This viral enzyme converts aciclovir into aciclovir monophosphate, a nucleotide analogue. The monophosphate is further converted into diphosphate by cellular guanylate kinase and into triphosphate by a number of cellular enzymes. In vitro, aciclovir triphosphate stops replication of herpes viral DNA. This is accomplished in three ways: </p> <p> <ol id="CD011367-list-0003"> <li> <p>competitive inhibition of viral DNA polymerase;</p> </li> <li> <p>incorporation into and termination of the growing viral DNA chain; and</p> </li> <li> <p>inactivation of the viral DNA polymerase (<a href="./references#CD011367-bbs2-0030" title="ElionGB . The biochemistry and mechanism of action of acyclovir. Journal of Antimicrobial Chemotherapy1983;12 Suppl B:9‐17. ">Elion 1983</a>; <a href="./references#CD011367-bbs2-0031" title="ElionGB . Acyclovir: discovery, mechanism of action, and selectivity. Journal of Medical Virology1993;Suppl 1:2‐6. ">Elion 1993</a>; <a href="./references#CD011367-bbs2-0051" title="Kerpel‐FroniusS , NyergesG , MésznerZ , EckhardtS , WalkerE , BridgenD . Intravenous acyclovir (ACV, Zovirax) therapy of varicella zoster infections in immunologically endangered patients. Orvosi Hetilap1983;124(48):2913‐8. ">Kerpel‐Fronius 1983</a>). </p> </li> </ol> </p> </section> <section id="CD011367-sec-0032"> <h4 class="title">Corticosteroids</h4> <p>Corticosteroids are powerful endogenous immunosuppressors, especially for the innate immune response and the subsequent inflammatory reaction (<a href="./references#CD011367-bbs2-0032" title="EspositoS , PicciolliI , SeminoM , PrincipiN . Steroids and childhood encephalitis. Pediatric Infectious Disease Journal2012;31:759‐60. ">Esposito 2012</a>; <a href="./references#CD011367-bbs2-0064" title="McKayLI , CidlowskiJA . Molecular control of immune/inflammatory responses: interactions between nuclear factor‐kappa B and steroid receptor‐signaling pathways. Endocrine Reviews1999;20(4):435‐59. ">McKay 1999</a>). Experimental data indicate that they may attenuate central nervous system damage by reducing cytokine and prostaglandin production, and limiting the nitric oxide concentration induced by the increased expression of immunological nitric oxide synthase (<a href="./references#CD011367-bbs2-0064" title="McKayLI , CidlowskiJA . Molecular control of immune/inflammatory responses: interactions between nuclear factor‐kappa B and steroid receptor‐signaling pathways. Endocrine Reviews1999;20(4):435‐59. ">McKay 1999</a>; <a href="./references#CD011367-bbs2-0065" title="Meyding‐LamadéU , SeyferS , HaasJ , DvorakF , KehmR , LamadéW , et al. Experimental herpes simplex virus encephalitis: inhibition of the expression of inducible nitric oxide synthase in mouse brain tissue. Neuroscience Letters2002;318:21‐4. ">Meyding‐Lamadé 2002</a>). Dexamethasone represses lipopolysaccharide‐induced nuclear factor kappa‐light‐chain‐enhancer of activated B cells (NF‐κB) activation in the brain (<a href="./references#CD011367-bbs2-0038" title="GlezerI , MunhozCD , KawamotoEM , MarcourakisT , AvellarMC , ScavoneC . MK‐801 and 7‐Ni attenuate the activation of brain NF‐kappa B induced by LPS. Neuropharmacology2003;45:1120‐9. ">Glezer 2003</a>); cortisol can abolish stimulated interleukin (IL)‐1β; and tumour necrosis factor (TNF)‐α gene expression in microglial cells. Ultimately, the effects of corticosteroids lead to a decrease in proinflammatory signal transduction pathways and gene expression, which is an essential endogenic mechanism to avoid exaggerated responses during immunogenic challenges (<a href="./references#CD011367-bbs2-0074" title="SergerieY , BoivinG , GosselinD , RivestS . Delayed but not early glucocorticoid treatment protects the host during experimental herpes simplex virus encephalitis in mice. Journal of Infectious Diseases2007;195:817‐25. ">Sergerie 2007</a>). </p> </section> </section> <section id="CD011367-sec-0033"> <h3 class="title" id="CD011367-sec-0033">Why it is important to do this review</h3> <p>There remains significant mortality and morbidity from childhood encephalitis despite standard treatment. Effective immunomodulatory strategies could improve outcomes in terms of reduce mortality and morbidity. Several previous reports point to a possible beneficial effect of IVIG in different forms of encephalitis (<a href="./references#CD011367-bbs2-0021" title="CaramelloP , CantaF , BalbianoR , LipaniF , AriaudoS , DeAgostiniM , et al. Role of intravenous immunoglobulin administration in Japanese encephalitis. Clinical Infectious Diseases2006;43(12):1620‐1. [PUBMED: PMID 17109300] ">Caramello 2006</a>; <a href="http://Hacohen, Y., et al., Paediatric autoimmune encephalopathies: clinical features, laboratory investigations and outcomes in patients with or without antibodies to known central nervous system autoantigens. J Neurol Neurosurg Psychiatry, 2013. 84(7): p. 748-55." target="_blank">Hacohen 2013</a>; <a href="./references#CD011367-bbs2-0081" title="TitulaerMJ , McCrackenL , GabilondoI , ArmanguéT , GlaserC , IizukaT , et al. Treatment and prognostic factors for long‐term outcome in patients with anti‐NMDA receptor encephalitis: an observational cohort study. Lancet Neurology2013;12(2):157‐65. [PUBMED: PMCID: PMC3563251] ">Titulaer 2013</a>; <a href="./references#CD011367-bbs2-0088" title="WangSM , LeiHY , HuangMC , SuLY , LinHC , YuCK , et al. Modulation of cytokine production by intravenous immunoglobulin in patients with enterovirus 71‐associated brainstem encephalitis. Journal of Clinical Virology2006;37(1):47‐52. [PUBMED: PMID: 16861032] ">Wang 2006</a>). In one paediatric cohort study, IVIG was used in only 35% (17/48) of participants presenting with probable autoimmune encephalopathy (<a href="./references#CD011367-bbs2-0024" title="DalakasM . Mechanism of action of intravenous immunoglobulin and therapeutic considerations in the treatment of autoimmune neurologic diseases. Neurology1998;51(6 Suppl 5):2‐8. [PUBMED: PMID 9851723] ">Dalakas 1998</a>; <a href="./references#CD011367-bbs2-0041" title="HacohenY , WrightS , WatersP , AgrawalS , CarrL , CrossH , et al. Paediatric autoimmune encephalopathies: clinical features, laboratory investigations and outcomes in patients with or without antibodies to known central nervous system autoantigens. Journal of Neurology, Neurosurgery, and Psychiatry2013;84(7):748‐55. [PUBMED: 23175854] ">Hacohen 2013</a>); whilst in one prospective surveillance study, only 15% (6/40) of children with acute disseminated encephalomyelitis received IVIG (<a href="./references#CD011367-bbs2-0014" title="AbsoudM , LimMJ , ChongWK , DeGoedeC , FosterK , GunnyR , et al. Paediatric acquired demyelinating syndromes: incidence, clinical and magnetic resonance imaging features. Multiple Sclerosis2013;19(1):76‐86. [PUBMED: PMID: 22516794] ">Absoud 2013</a>; <a href="./references#CD011367-bbs2-0061" title="MarchioniE , RavagliaS , MontomoliC , TavazziE , MinoliL , BaldantiF , et al. Postinfectious neurologic syndromes: a prospective cohort study. Neurology2013;80(10):882‐9. [PUBMED: PMID: 23325908] ">Marchioni 2013</a>). </p> <p>However, there remains a lack of consensus amongst clinicians on the use of IVIG in childhood encephalitis and practice varies widely. This review therefore aims to provide a detailed analysis of existing data on the use of IVIG in the treatment of children with encephalitis and may provide additional supportive evidence to inform on its routine use in clinical practice. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD011367-sec-0034" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD011367-sec-0034"></div> <p>To assess the efficacy and safety of intravenous immunoglobulin (IVIG) as add‐on treatment for children with encephalitis. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD011367-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD011367-sec-0035"></div> <section id="CD011367-sec-0036"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD011367-sec-0037"> <h4 class="title">Types of studies</h4> <p>We included only RCTs and excluded uncontrolled or non‐randomised trials.</p> </section> <section id="CD011367-sec-0038"> <h4 class="title">Types of participants</h4> <section id="CD011367-sec-0039"> <h5 class="title">Inclusion criteria</h5> <p>Children aged six weeks to 17 years with a clinical diagnosis of acute (symptoms present within 24 hours prior to hospitalisation) or subacute (symptoms present between 24 hours and four weeks prior to hospitalisation) encephalitis as defined by the trial investigators. Since there is the likelihood of variation in how encephalitis is diagnosed, where the eligibility of participants in an identified study (in terms of the diagnosis of encephalitis) was in doubt, we planned to apply predefined diagnostic criteria adapted from the Consensus Statement of the International Encephalitis Consortium (<a href="./references#CD011367-bbs2-0086" title="VenkatesanA , TunkelAR , BlochKC , LauringAS , SejvarJ , BitnunA , et al. Case definitions, diagnostic algorithms, and priorities in encephalitis: consensus statement of the international encephalitis consortium. Clinical Infectious Diseases2013;57(8):1114‐28. [PUBMED: PMID 23861361] ">Venkatesan 2013</a>) to ascertain eligibility. We planned to agree a diagnosis of encephalitis if the following features were present. </p> <p> <ul id="CD011367-list-0004"> <li> <p>Altered mental state (reduced or altered conscious level, irritability, altered personality or behaviour, lethargy), and any two of the following: </p> </li> </ul> <ul class="plain" id="CD011367-list-0005"> <li> <ul id="CD011367-list-0006"> <li> <p>brain imaging evidence consistent with encephalitis or immune‐mediated encephalopathy that appears acute in onset; </p> </li> <li> <p>cerebrospinal fluid (CSF) pleocytosis: CSF white blood count of 5 cells/mm<sup>3</sup> or greater; </p> </li> <li> <p>presence of autoantibodies such as N‐methyl D‐aspartate receptor antibodies, and voltage‐gated potassium channel antibodies, in CSF or blood (or both); </p> </li> <li> <p>generalised or partial seizures not fully attributable to a pre‐existing seizure disorder;</p> </li> <li> <p>new‐onset focal neurological signs (including movement disorders);</p> </li> <li> <p>abnormality on electroencephalogram (EEG) or cerebral function analysis monitor that is consistent with encephalitis and not attributable to another cause; </p> </li> <li> <p>fever 38 ºC or greater within 72 hours before or after presentation to hospital.</p> </li> </ul> </li> </ul> </p> </section> <section id="CD011367-sec-0040"> <h5 class="title">Exclusion criteria</h5> <p>Children with chronic encephalitis (i.e. where presenting symptoms had lasted longer than four weeks). </p> <p>Children with known hypersensitivity to IVIG.</p> </section> </section> <section id="CD011367-sec-0041"> <h4 class="title">Types of interventions</h4> <p> <ul id="CD011367-list-0007"> <li> <p>For experimental trials, the intervention group was IVIG (regardless of dose, time of commencement, and duration of treatment) used either alone or in combination with standard care. The control group was standard care alone or in combination with placebo. Standard care was defined as intravenous aciclovir or corticosteroid therapy (methylprednisolone, prednisone, prednisolone, or dexamethasone), or both. </p> </li> <li> <p>For cohort and case‐control studies, intervention was any treatment regimen that included IVIG while the control group was any treatment regimen without IVIG. </p> </li> </ul> </p> </section> <section id="CD011367-sec-0042"> <h4 class="title">Types of outcome measures</h4> <section id="CD011367-sec-0043"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD011367-list-0008"> <li> <p>Proportion of participants with significant disability (= 'poor outcome') at six months after treatment. </p> <ul id="CD011367-list-0009"> <li> <p>Significant disability using any validated disability assessment scale such as (but not limited to) the Glasgow Outcome Scale Extended (score of 2 or less) (<a href="./references#CD011367-bbs2-0019" title="BeersSR , WisniewskiSR , Garcia‐FilionP , TianY , HahnerT , BergerRP , et al. Validity of a pediatric version of the Glasgow Outcome Scale ‐ Extended. Journal of Neurotrauma2012;10(6):1126‐39. ">Beers 2012</a>), Liverpool Outcome Score (score of 2 or less) (<a href="./references#CD011367-bbs2-0056" title="LewthwaiteP , BegumA , OoiM , FaragherB , LaiBF , SandaraduraI , et al. Disability after encephalitis: development and validation of a new outcome score. Bulletin of the World Health Organization2010; Vol. 88, issue 8:584‐92. ">Lewthwaite 2010</a>), or the modified Rankin Scale (score of 4 or more) (<a href="./references#CD011367-bbs2-0084" title="vanSwietenJC , KoudstaalPJ , VisserMC , SchoutenHJ , vanGijnJ . Interobserver agreement for the assessment of handicap in stroke patients. Stroke1988; Vol. 19, issue 5:604‐7. ">van Swieten 1988</a>). </p> </li> </ul> </li> </ul> <ul id="CD011367-list-0010"> <li> <p>Proportion of participants with at least one serious adverse event as defined in the trial. </p> </li> </ul> </p> <p>Where the definition of a serious adverse event was not clearly defined, we used the definition from the International Conference on Harmonisation (ICH) Harmonised Tripartite Guideline (<a href="./references#CD011367-bbs2-0047" title="International Conference on Harmonisation. ICH harmonised tripartite guideline clinical safety data management: definitions and standards for expedited reporting E2A. Current step 4 version. International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use. 27 October 1994. www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E2A/Step4/E2A_Guideline.pdf (accessed prior to 25 September 2017). ">ICH 1994</a>), which defines a serious adverse event as any adverse event that results in any of the following outcomes: is life‐threatening, results in death, requires prolongation of hospital stay, results in persistent or significant disability/incapacity, congenital abnormality. Mortality was reported separately. </p> </section> <section id="CD011367-sec-0044"> <h5 class="title">Secondary outcomes</h5> <section id="CD011367-sec-0045"> <h6 class="title">Short term (during hospital admission)</h6> <p> <ul id="CD011367-list-0011"> <li> <p>Proportion of participants with significant disability at discharge.</p> </li> <li> <p>Glasgow Outcome Score at discharge (either as continuous or categorised data, as reported in the trial). </p> </li> <li> <p>Length of hospital stay (either as continuous or categorised data, as reported in the trial). </p> </li> <li> <p>Proportion of participants requiring invasive ventilation and duration (either as continuous or categorised data, as reported in the trial). </p> </li> <li> <p>Time to fever resolution (either as continuous or categorised data, as reported in the trial). </p> </li> <li> <p>Time to stop spasms (either as continuous or categorised data, as reported in the trial). </p> </li> <li> <p>Time to regain consciousness (either as continuous or categorised data, as reported in the trial). </p> </li> <li> <p>Time to resolution of neuropathic symptoms (either as continuous or categorised data, as reported in the trial). </p> </li> </ul> </p> </section> <section id="CD011367-sec-0046"> <h6 class="title">Long term (at six months' postdischarge from hospital)</h6> <p> <ul id="CD011367-list-0012"> <li> <p>Any cognitive impairment as defined in the trial (binary: yes/no), major cognitive disability as defined by in the trial (binary: yes/no), and mean cognitive scores using any validated age‐appropriate psychometric instrument. </p> </li> </ul> <ul class="plain" id="CD011367-list-0013"> <li> <ul id="CD011367-list-0014"> <li> <p>Bayley Scales of Infant Development (<a href="./references#CD011367-bbs2-0018" title="BayleyN . Bayley Scales of Infant and Toddler Development. Technical Manual. 3rd Edition. San Antonio (TX): Harcourt Assessment, 2006. ">Bayley 2006</a>). </p> </li> <li> <p>Wechsler Preschool and Primary Scale of Intelligence (<a href="./references#CD011367-bbs2-0089" title="WechslerD . Wechsler Preschool and Primary Scale of Intelligence (WPPSI ‐ III). 3rd Edition. Ontario (Canada): Pearson Canada Assessment Inc, 2002. ">Wechsler 2002</a>). </p> </li> <li> <p>Wechsler Intelligence Scale for Children (<a href="./references#CD011367-bbs2-0090" title="WechslerD . Wechsler Intelligence Scale for Children (WISC‐IV). 4th Edition. Ontario (Canada): Pearson Canada Assessment Inc, 2003. ">Wechsler 2003</a>). </p> </li> </ul> </li> </ul> <ul id="CD011367-list-0015"> <li> <p>Poor adaptive functioning as defined in the trial (binary: yes/no) or adaptive behaviour scores less than two standard deviations from the mean, using any validated age‐appropriate scale. </p> </li> </ul> <ul class="plain" id="CD011367-list-0016"> <li> <ul id="CD011367-list-0017"> <li> <p>Vineland Adaptive Behaviour Scales (<a href="./references#CD011367-bbs2-0075" title="SparrowSS , BallaDA , CicchettiDV . Vineland adaptive behavior scales. American Guidance Service, Circle Pines. Journal of Educational Measurement1986;23(4):389‐91. ">Sparrow 1986</a>; <a href="./references#CD011367-bbs2-0076" title="SparrowSS , CarterAS , CicchettiDV . Vineland Screener: Overview, Reliability, Validity, Administration and Scoring. Interview Edition, Survey Form Manual. New Haven (CT): Yale University Child Study Centre, 1993. ">Sparrow 1993</a>). </p> </li> <li> <p>Adaptive Behaviour Assessment System (<a href="./references#CD011367-bbs2-0043" title="HarrisonPL , OaklandT . ABAS®‐II Adaptive Behavior Assessment System®. 2nd Edition. San Antonio (TX): Harcourt Assessment, 2003. ">Harrison 2003</a>). </p> </li> <li> <p>Behavior Assessment System for Children Parent Rating Scales (<a href="./references#CD011367-bbs2-0070" title="ReynoldsCR , KamphausRW . Assessment of effective intervention. Behavior Assessment System for Children (BASC‐2). 2nd Edition. Vol. 32, Crowley (TX): AGS Publishing, 2004:121‐4. ">Reynolds 2004</a>). </p> </li> </ul> </li> </ul> <ul id="CD011367-list-0018"> <li> <p>Quality of life assessment scores obtained using any validated age‐appropriate tool.</p> </li> </ul> <ul class="plain" id="CD011367-list-0019"> <li> <ul id="CD011367-list-0020"> <li> <p>Pediatric Quality of Life Inventory (PedsQL) (<a href="./references#CD011367-bbs2-0085" title="VarniJW , SeidM , RodeCA . The PedsQL™: measurement model for the pediatric quality of life inventory. Medical Care1999; Vol. 37, issue 2:126‐39. ">Varni 1999</a>). </p> </li> <li> <p>Health‐related quality of life (<a href="./references#CD011367-bbs2-0063" title="MatzaLS , SwensenAR , FloodEM , SecnikK , LeidyNK . Assessment of health‐related quality of life in children: a review of conceptual, methodological, and regulatory issues. Value in Health2004;7:79‐92. ">Matza 2004</a>). </p> </li> </ul> </li> </ul> <ul id="CD011367-list-0021"> <li> <p>Number of seizures per participant and the proportion of participants with new diagnosis of epilepsy. </p> </li> </ul> </p> </section> </section> </section> </section> <section id="CD011367-sec-0047"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD011367-sec-0048"> <h4 class="title">Electronic searches</h4> <p>We conducted a systematic search without language restrictions to identify all relevant published and unpublished RCTs using the optimally sensitive strategy developed for Cochrane for the identification of RCTs (<a href="./references#CD011367-bbs2-0055" title="LefebvreC , ManheimerE , GlanvilleJ . Chapter 6: Searching for studies. In: Higgins J, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Lefebvre 2011</a>). The Trials Search Co‐ordinator of the Cochrane Multiple Sclerosis and Rare Diseases of the Central Nervous System Group ran the initial searches for all prospectively registered and ongoing trials in the following databases: </p> <p> <ul id="CD011367-list-0022"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL 2016, Issue 9);</p> </li> <li> <p>MEDLINE (PubMed) (1966 to 30 September 2016);</p> </li> <li> <p>Embase (Embase.com) (1974 to 30 September 2016);</p> </li> <li> <p>Cumulative Index to Nursing and Allied Health Literature (CINAHL) (EBSCO host) (1981 to 30 September 2016); </p> </li> <li> <p>ClinicalTrials.gov (<a href="http://clinicaltrials.gov" target="_blank">clinicaltrials.gov</a>); </p> </li> <li> <p>World Health Organization (WHO) International Clinical Trials Registry Portal (ICTRP) search portal (<a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch/</a>). </p> </li> </ul> </p> <p>The keywords used to search for trials for this review are listed in <a href="./appendices#CD011367-sec-0112">Appendix 1</a>. </p> <p>In addition, two review authors (MI, NGM) searched the Global Health Library (Virtual Health Library) (<a href="http://www.globalhealthlibrary.net/php/index.php" target="_blank">www.globalhealthlibrary.net/php/index.php</a>) and Science Citation Index Expanded (SCI‐EXPANDED) &amp; Conference Proceedings Citation Index‐Science (CPCI‐S) (Web of Science) (1945 to date) using a combination of free‐text and MeSH terms to describe the population and intervention as illustrated in <a href="https://archie.cochrane.org/sections/documents/view?document=z1402140937483174872890250876330%26format=REVMAN#APP-01" target="_blank">Appendix 1</a>. We applied the search filter 'Cochrane Highly Sensitive Search Strategy for identifying randomised trials in MEDLINE: sensitivity‐ and precision‐maximizing version (2008 revision); PubMed format' to MEDLINE and adaptations of it to the other databases except CENTRAL (<a href="./references#CD011367-bbs2-0045" title="HigginsJPT , GreenS , editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). We applied no language or date limits to our search. We identified non‐RCTs using the same search strategy, without the RCT/controlled clinical trial filters. </p> </section> <section id="CD011367-sec-0049"> <h4 class="title">Searching other resources</h4> <p>We screened reference lists of included studies and related reviews for additional trials. In addition, we contacted experts working in this field to enquire about any ongoing trials or unpublished data. </p> </section> </section> <section id="CD011367-sec-0050"> <h3 class="title" id="CD011367-sec-0050">Data collection and analysis</h3> <section id="CD011367-sec-0051"> <h4 class="title">Selection of studies</h4> <p>Two review authors (MI, NGM) independently assessed the eligibility of studies to be included in this review using an eligibility form. We performed screening at two levels. Level one screening involved a broad screen of title or abstracts (or both), as available. In all instances where the title or abstract (or both) suggested that the report related to a trial reporting on the use of IVIG in the treatment of encephalitis in a group of children, we retrieved the full‐text article for further assessment. Level two screening involved a comprehensive assessment of the full text of retrieved articles to ascertain eligibility. We compared multiple reports of the same study, and used the most comprehensive report. We linked multiple publications together as companion reports, but excluded true duplicates. We documented the exclusion of any study from the review, and have described the reasons for exclusion in the <a href="./references#CD011367-sec-0129" title="">Characteristics of excluded studies</a> table. We resolved any disagreements by discussion between the two review authors (MI and NGM) without the need to consult the other coauthors (MA, AJP). </p> </section> <section id="CD011367-sec-0052"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (MI and NGM) extracted the data from studies independently using a standardised data extraction sheet, accompanied by a data extraction guideline that was developed after piloting the data extraction form. The data extraction form included information on outcomes as listed in the primary and secondary objectives of the review as well as data related to the study characteristics, participant characteristics, interventions and comparators, follow‐up details, declaration of interest for the primary investigators, and source of funding for each study. Where the relevant data were unclear or missing, we contacted the publication author to clarify this or provide the missing data. We resolved disagreements by discussion between two review authors (MI and NGM). We managed and analysed all data using Review Manager 5 software (<a href="./references#CD011367-bbs2-0069" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). </p> </section> <section id="CD011367-sec-0053"> <h4 class="title">Assessment of risk of bias in included studies</h4> <section id="CD011367-sec-0054"> <h5 class="title">Experimental studies</h5> <section id="CD011367-sec-0055"> <h6 class="title">Randomised controlled trials</h6> <p>Two review authors (MI and NGM) assessed the risk of bias in the included trials using Cochrane's tool for assessing risk of bias to evaluate the internal validity of the design and conduct of included studies (<a href="./references#CD011367-bbs2-0045" title="HigginsJPT , GreenS , editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). This tool describes a number of domains to be judged on the adequacy of each study: selection bias (sequence generation and allocation concealment), performance bias (blinding of participants and personnel), detection bias (blinding of outcome assessors for each outcome separately), attrition bias (incomplete outcome data for each outcome separately), reporting bias (selective outcome reporting), and other bias. </p> <p>To classify the methodological quality of studies, we considered bias for selection, detection, and attrition. We judged a study as having a high risk of attrition bias based on either the reasons for missing data or the difference between the percentage of participants missing in the control and treatment groups. We used the summary quality assessment at the analysis stage as a means of interpreting the results. For each domain and for the summary assessment, we assigned the risk of bias categories as: low risk of bias, plausible bias unlikely to seriously alter the results; unclear risk of bias, plausible bias that raises some doubt about the results; and high risk of bias, plausible bias that seriously weakens confidence in the results (<a href="./references#CD011367-bbs2-0045" title="HigginsJPT , GreenS , editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). We rated a study as 'low risk of bias' when none of the three domains was affected, 'high risk of bias' when at least one of the three domains was affected and 'unclear risk of bias' in all other cases. We considered the risk of bias in included studies when we interpreted the review's results. We compared the outcomes listed in the study protocol, where this was accessible in the public domain, with the outcomes reported in the published manuscript. There was no disagreement in assessing the risk of bias between review authors. </p> </section> <section id="CD011367-sec-0056"> <h6 class="title">Controlled clinical trials, case‐control studies, and cohort studies</h6> <p>We did not include case‐control or cohort studies in this review. We planned to evaluate the quality of case‐control and cohort studies (prospective and retrospective) using the appropriate Newcastle‐Ottawa Scales and considering the risk of bias in the following domains: selection: case and control (case‐control studies) or exposed and non‐exposed (cohort studies), comparability, and assessment of exposure (case‐ control studies) or outcome (cohort studies) (<a href="https://archie.cochrane.org/sections/documents/view?document=z1402140937483174872890250876330%26format=REVMAN#APP-02" target="_blank">Appendix 2</a>; <a href="https://archie.cochrane.org/sections/documents/view?document=z1402140937483174872890250876330%26format=REVMAN#APP-03" target="_blank">Appendix 3</a>). To assess the methodological quality of non‐RCTs, we planned to consider the risk of bias in all three domains listed above and to rate a study as 'high risk of bias' if a least one of the three domains was affected and 'low risk of bias' where none of the domains was affected and 'unclear risk of bias' in all other cases. We planned to assess the quality of non‐randomised studies in relation to the presence of potential confounders that could make interpretation of the results difficult. </p> </section> <section id="CD011367-sec-0057"> <h6 class="title">Criteria for assessing quality of safety data for all studies</h6> <p>We assessed the risk of bias for serious adverse events by considering specific factors that may have had a large influence on the adverse events data. We evaluated methods for monitoring and detecting a serious adverse event for each study as below. </p> <p> <ul id="CD011367-list-0023"> <li> <p>Did the researchers actively monitor for serious adverse events (low risk of bias), or did they simply provide spontaneous reporting of serious adverse events that arose (high risk of bias)? </p> </li> <li> <p>Did the authors define serious adverse events according to an accepted international classification and report the number of serious adverse events? </p> </li> </ul> </p> </section> </section> </section> <section id="CD011367-sec-0058"> <h4 class="title">Measures of treatment effect</h4> <p>We carried out statistical analyses using Review Manager 5 software (<a href="./references#CD011367-bbs2-0069" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). For dichotomous data (e.g. mortality), we calculated the risk ratio (RR) with 95% confidence intervals (CIs) to express the effect size. We planned to calculate the number needed to treat for an additional beneficial outcome (NNTB) and additional harmful outcome (NNTH). However, this was not calculated because the findings of the meta‐analysis for mortality did not show a statistically significant reduction or increase in risk difference (RD) between the study groups. Only one of the included studies reported on mortality as a binary outcome (number of deaths/total number of participants in each group), with no survival data presented. Therefore, we were unable to analyse mortality as a hazard ratio as planned. For continuous data (e.g. length of hospital stay), we calculated mean differences (MD) with 95% CIs. For both individual and pooled data, we reported effect estimates from both continuous and dichotomous data as P values and 95% CI. </p> </section> <section id="CD011367-sec-0059"> <h4 class="title">Unit of analysis issues</h4> <p>In all studies, we used the individual participant as the unit of analysis. We found no cross‐over trials. </p> </section> <section id="CD011367-sec-0060"> <h4 class="title">Dealing with missing data</h4> <p>Where contact details were available, we contacted the main authors to obtain additional data not reported in the published articles. We planned to perform an intention‐to‐treat analysis if this was necessary and possible. </p> </section> <section id="CD011367-sec-0061"> <h4 class="title">Assessment of heterogeneity</h4> <p>We tested the results from the studies for heterogeneity using the Chi<sup>2</sup> test (<a href="./references#CD011367-bbs2-0044" title="HigginsT , ThompsonG , DeeksJ , AltmanD . Measuring inconsistencies in meta‐analysis. BMJ2003;327(414):557‐60. [PUBMED: PMCID: PMC192859; PUBMED: PMID: 12958120] ">Higgins 2003</a>). We assessed statistical heterogeneity by visually inspecting forest plots and by using the Chi<sup>2</sup> test for heterogeneity (with a P &lt; 0.10 for significance). We used the I<sup>2</sup> statistic as a measure of inconsistency across studies. We evaluated the degree of heterogeneity according to the following I<sup>2</sup> thresholds: </p> <p> <ul id="CD011367-list-0024"> <li> <p>0% to 40%: might not be important;</p> </li> <li> <p>30% to 60%: may represent moderate heterogeneity;</p> </li> <li> <p>50% to 90%: may represent substantial heterogeneity;</p> </li> <li> <p>75% to 100%: considerable heterogeneity.</p> </li> </ul> </p> <p>If substantial statistical heterogeneity was found to be present according to the Chi<sup>2</sup> test for heterogeneity or I<sup>2</sup> statistic, we performed meta‐analysis with a random‐effects model rather than a fixed‐effect model. </p> </section> <section id="CD011367-sec-0062"> <h4 class="title">Assessment of reporting biases</h4> <p>The process of reporting bias is described in the <a href="https://archie.cochrane.org/sections/documents/view?document=z1402140937483174872890250876330%26format=REVMAN#QUALITY_ASSESSMENT" target="_blank">Assessment of risk of bias in included studies</a> section. We assessed studies for reporting bias by analysing inclusion and exclusion criteria and blinding of participants and observers. We also analysed primary and secondary outcomes for any reporting biases. We planned to assess reporting bias by visually inspecting the funnel plot to detect the presence of asymmetry if more than 10 studies were found. We did not perform this since the number of studies included did not reach the prespecified threshold and as such the power of the test was too low. </p> </section> <section id="CD011367-sec-0063"> <h4 class="title">Data synthesis</h4> <section id="CD011367-sec-0064"> <h5 class="title">Meta‐analysis</h5> <p>When more than one study reported continuous or dichotomous data, we pooled the results. We pooled estimates using a fixed‐effect model meta‐analysis where trials were sufficiently homogenous (I<sup>2</sup> &lt; 50%). In contrast, we used a random‐effects model where there was sufficient heterogeneity to suggest that treatment effects might differ between trials (I<sup>2</sup> &gt; 50%). If data for an outcome were reported using different measurement scales or defined threshold values that could not be adjusted to a uniform scale/statistic (e.g. mean and median for length of hospital stay), we performed a pooled analysis of only those data that had been reported in a similar way and a qualitative description of the results of the other studies not included in the meta‐analysis in the text. Where trials reported binary outcomes such as disability ('poor outcome'), cognitive impairment, or major cognitive disability using different measurement scales or threshold value definitions, or both, we performed only a qualitative description of results. For studies with multiple intervention groups, we performed separate meta‐analyses synthesising each of the different comparisons of interventions for each of the different outcomes. </p> </section> </section> <section id="CD011367-sec-0065"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Since clinical outcomes for encephalitis may vary depending on factors such as aetiology, baseline immune status, dose, and timing of IVIG administration as well as timing of standard therapy given, we planned to compare the following possible subgroups: </p> <p> <ul id="CD011367-list-0025"> <li> <p>different encephalitis types (infective, immune mediated and unknown aetiology);</p> </li> <li> <p>primary or secondary immunodeficiency versus immunocompetent people;</p> </li> <li> <p>low dose IVIG (less than 1 g/kg) versus high dose (1 g/kg or greater);</p> </li> <li> <p>early (within five days of hospital admission) versus late (beyond five days of hospital admission) IVIG treatment; </p> </li> <li> <p>early (within 48 hours of admission) versus late (beyond 48 hours of admission) institution of standard therapy. </p> </li> </ul> </p> <p>However, because of limited available data subgroup analyses were not performed.</p> </section> <section id="CD011367-sec-0066"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to perform sensitivity analysis to assess whether the effect of IVIG varied with the exclusion of studies rated as high or unclear risk of bias. If the results observed remain unchanged, we planned to consider the evidence to be robust. We did not perform a sensitivity analysis because the risk of bias among the included studies was highly diverse and none of the included studies was of adequate methodological quality based on our prespecified definition. </p> <section id="CD011367-sec-0067"> <h5 class="title">'Summary of findings' table</h5> <p>We created a 'Summary of findings' table using the following prespecified outcomes:</p> <p> <ul id="CD011367-list-0026"> <li> <p>significant disability;</p> </li> <li> <p>at least one serious adverse event;</p> </li> <li> <p>length of hospital stay.</p> </li> </ul> </p> <p>We used the five (GRADE) considerations (study limitations, consistency of effect, imprecision, indirectness, and publication bias) to assess the quality of a body of evidence as it related to the studies that contributed data to the meta‐analyses for the prespecified outcomes. We used methods and recommendations described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011367-bbs2-0045" title="HigginsJPT , GreenS , editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>), using GRADEpro software (<a href="./references#CD011367-bbs2-0039" title="GRADE Working Group, McMaster University. GRADEprofiler (GRADEpro). Hamilton (ON): GRADE Working Group, McMaster University, 2014. ">GRADEpro 2014</a>). We justified all decisions to downgrade or upgrade the quality of studies using footnotes and we made comments to aid reader's understanding of the review where necessary. </p> <p>We planned to include the following prespecified outcomes in the 'Summary of findings' table: </p> <p> <ul id="CD011367-list-0027"> <li> <p>need for and duration of invasive ventilation;</p> </li> <li> <p>cognition;</p> </li> <li> <p>poor adaptive function;</p> </li> <li> <p>quality of life;</p> </li> <li> <p>new‐onset epilepsy.</p> </li> </ul> </p> <p>However, none of the included studies reported on these outcomes.</p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD011367-sec-0068" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD011367-sec-0068"></div> <section id="CD011367-sec-0069"> <h3 class="title">Description of studies</h3> <section id="CD011367-sec-0070"> <h4 class="title">Results of the search</h4> <p>The process of study identification and selection is shown in <a href="#CD011367-fig-0001">Figure 1</a>. The search strategy retrieved 822 titles (MEDLINE (160), Embase (433), the Cochrane Library (11), CINAHL (57) Clinicaltrials.gov (one), Web of Science (23), Global Health Library (135), and DARE (two). One additional record was retrieved through Google search. Of the 681 articles remaining after removal of duplicates, 668 were excluded following level one screening because the titles/abstracts of the articles did not suggest that the report related to a trial reporting on the use of IVIG in the treatment of encephalitis in a child or group of children. Therefore, 13 articles had the potential to be included in this review. We retrieved the full article for all 13 papers and after reading the full text, considered three articles of three trials to be eligible for inclusion. We found one ongoing trial in the UK of IVIG in childhood encephalitis but this was not included since results of the study are not yet available (<a href="./references#CD011367-bbs2-0013" title="NCT02308982 . Investigating the role of early intravenous immunoglobulin treatment for children with encephalitis [A phase III multi‐centre randomised, double blind, placebo controlled trial to assess the role of intravenous immunoglobulin in the management of children with encephalitis]. clinicaltrials.gov/ct2/show/record/NCT02308982 Date first received; 1 December 2014. ">NCT02308982</a>). One trial is awaiting classification (<a href="./references#CD011367-bbs2-0012" title="FanJ‐L . The clinical observation of the high dose intravenous immunoglobulin for severe viral encephalitis. Internal Medicine of China2010;02:118‐9. ">Fan 2010</a>). This is a study of high‐dose immunoglobulin in severe viral encephalitis and included both children and adults. The findings were presented as aggregate data and the results for children only were not presented separately. We attempted to contact the authors for this study but no contact details have been found so far. We contacted the main author of one of the included studies (<a href="./references#CD011367-bbs2-0002" title="RayamajhiA , NightingaleS , BhattaNK , SinghR , LedgerE , BistaKP , et al. A preliminary randomized double blind placebo‐controlled trial of intravenous immunoglobulin for Japanese encephalitis in Nepal. PloS One2015;10(4):e0122608. ">Rayamajhi 2015</a>), but we were unable to obtain the information required. </p> <div class="figure" id="CD011367-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram. RCT: randomised controlled trial." data-id="CD011367-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011367.pub2/media/CDSR/CD011367/image_n/nCD011367-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram. RCT: randomised controlled trial.</p> </div> </div> </div> </section> <section id="CD011367-sec-0071"> <h4 class="title">Included studies</h4> <p>Three studies met the criteria to be included. See <a href="./references#CD011367-sec-0128" title="">Characteristics of included studies</a> table. </p> <p><a href="./references#CD011367-bbs2-0001" title="ChenD‐M , LiS‐N . The clinical observation of high dose immunoglobulin for children viral encephalitis. Chinese Journal of Primary Medicine and Pharmacy2006;13(5):816‐7. ">Chen 2006</a> was an RCT of IVIG in addition to standard treatment in children with viral encephalitis. Between February 2000 to October 2004, 62 children aged seven months to 12 years with a diagnosis of viral encephalitis defined according to the guidelines and symptoms described in "<i>Applied Pediatrics</i>" sixth edition were enrolled and randomly split into an observation group (32 children) and a control group (30 children). The proportion of enrolled boys was 58.1%. The mean (± standard deviation (SD) ages for children in the observation were 6.16 ± 2.38 years and for children in the control group were 5.88 ± 2.46 years. Baseline characteristics between both groups (gender, age, clinical symptoms and signs, severity of disease, and duration of hospital stay) did not differ significantly. Both groups underwent conventional treatment which included fever and spasm reductions, reduction of intracranial pressure, maintenance of hydration, electrolyte, and acid‐base balance, application of hormones and antivirals, prevention and treatment of infections, and upkeep of morale. In addition, the observation group received IVIG 400 mg/kg/day for three to five days. Outcome measures included time taken for fever reduction, length of seizures, time taken to regain consciousness, and duration of stay in hospital. The authors concluded that children who received IVIG treatment had significantly quicker recovery time in terms of days to reduction of fever, regaining of consciousness level, and resolution of spasms. Additionally, the authors reported a significantly shorter duration of hospital stay in the observation compared with the control group. </p> <p><a href="./references#CD011367-bbs2-0002" title="RayamajhiA , NightingaleS , BhattaNK , SinghR , LedgerE , BistaKP , et al. A preliminary randomized double blind placebo‐controlled trial of intravenous immunoglobulin for Japanese encephalitis in Nepal. PloS One2015;10(4):e0122608. ">Rayamajhi 2015</a> was a pilot feasibility RCT conducted at two centres in Nepal from May to June 2009. Children were aged one to 14 years with clinically diagnosed acute encephalitis syndrome using predefined diagnostic criteria (history of fever that lasted less than 14 days, altered consciousness defined as Glasgow Coma Score less than 15 with or without a history of seizures, and consistent CSF findings, i.e. white cell count less than 1000 cells/mm<sup>3</sup> with no organisms on Gram stain and CSF:plasma glucose ratio greater than 40%) and suspected to have Japanese encephalitis. Children were excluded if they had a single seizure lasting less than 15 minutes with full recovery of consciousness within 60 minutes (as these were assumed to have had a febrile convulsion); positive blood slide or rapid antigen test for <i>Plasmodium falciparum</i> parasites, clinical or laboratory (or both) features suggestive of bacterial meningitis where antibiotic treatment had already been commenced (for referred children); and a GCS less than 3 (out of 15) and were receiving artificial ventilation without signs of spontaneous respiration, and with absent oculocephalic reflex (as prior studies have shown an extremely low chance of meaningful recovery). Ethical approval and informed consent were obtained. Enrolled children were randomly allocated to receive either IVIG 400 mg/kg/day or an equivalent volume of 0.9% saline (placebo) for five days. Randomisation was stratified by centre using a variable block size of four, six, or eight, selected on a random basis. Participants were assessed at discharge and after three to six months. The reported primary objective was to assess the feasibility of a multicentre placebo‐controlled RCT of IVIG in a resource‐poor setting. Reported secondary outcomes were death or neurological sequelae at discharge or follow‐up, and adverse events. In addition, anti‐Japanese encephalitis virus (anti‐JEV) antibody titres were compared between children treated and not treated with IVIG. A total of 23 children were screened, 22 met the eligibility criteria and were enrolled. One child was not enrolled due to meeting an exclusion criterion. The proportion of enrolled boys was 54.5%. With the exception of CSF protein levels which were significantly higher in the IVIG group, baseline characteristics of the two study groups were comparable; the median age for both groups did not differ statistically and was five years for the IVIG group and seven years for the placebo (saline) group. No protocol breaches were reported. The authors reported that a trial of IVIG in Japanese encephalitis in Nepal is feasible and that IVIG may augment the development of neutralising antibodies in JEV‐positive people. </p> <p><a href="./references#CD011367-bbs2-0003" title="WuH , WanZ , LiuL , QiuL , XiulingD . Comparison of the clinical efficacy of immunoglobulin and interferon in the treatment of hand foot and mouth disease complicated with viral encephalitis. Chinese Journal of Primary Medicine and Pharmacy2014;21:3127‐8. ">Wu 2014</a> was an RCT comparing the clinical efficacy of gamma globulin in the treatment of hand, foot, and mouth disease (HFMD) complicated by viral encephalitis in children admitted to a general hospital in China between January 2009 and January 2013. The diagnosis of HFMD was based on published definition guidelines by the Chinese Department of Ministry of Health. Ethical approval and consent were obtained. Eighty children (aged one to six years) were enrolled and randomly assigned to three groups: experimental group one (Ex1; 27 children), experimental group two (Ex2; 26 children), and control group (CG; 27 children); according to a random‐sampling table. There was no statistically significant difference between the groups in age, gender, and duration of illness. The CG was given conventional comprehensive treatment including dehydration, reduction of intracranial pressure, nutritional support, anti‐infection treatment, keeping the skin clean, and general precautions to prevent infection. Children in Ex1, were given intravenous injection of human blood gamma globulin at 400 mg/kg/day for three consecutive days, in addition to the comprehensive treatment. Children in Ex2 received a spray of human interferon alfa‐2h, one or two sprays per time, three times per day on three consecutive days, in addition to the comprehensive treatment. Children with underlying immune problems and who were unconscious were excluded. The outcomes measured included time for fever to subside, convulsions to be under control, rashes to subside, neuropathic symptoms to subside, and mean stay in hospital. Adverse events occurring in children in the two experimental groups were compared. The authors concluded that the treatment of children with HFMD complicated by encephalitis with gamma globulin and human interferon can relieve clinical symptoms, improve prognosis, and reduce sequelae. </p> </section> <section id="CD011367-sec-0072"> <h4 class="title">Excluded studies</h4> <p>We excluded eight studies at level two screening due to their study design. More details about excluded studies are detailed in the <a href="./references#CD011367-sec-0129" title="">Characteristics of excluded studies</a> table. </p> <section id="CD011367-sec-0073"> <h5 class="title">Ongoing studies</h5> <p>We identified one ongoing multicentre, double‐blind, placebo‐controlled RCT of IVIG in childhood encephalitis (<a href="./references#CD011367-bbs2-0013" title="NCT02308982 . Investigating the role of early intravenous immunoglobulin treatment for children with encephalitis [A phase III multi‐centre randomised, double blind, placebo controlled trial to assess the role of intravenous immunoglobulin in the management of children with encephalitis]. clinicaltrials.gov/ct2/show/record/NCT02308982 Date first received; 1 December 2014. ">NCT02308982</a>). In the trial, 308 children aged six weeks to 16 years with encephalitis are planned to be recruited and randomised 1:1 to receive two doses (1 g/kg/dose) of either IVIG or matching placebo in addition to standard treatment. Follow‐up is for 12 months' post randomisation and the primary outcome will be assessed using the Glasgow Outcome Score Extended ‐ Pediatric version at 12 months' post randomisation. </p> </section> </section> </section> <section id="CD011367-sec-0074"> <h3 class="title">Risk of bias in included studies</h3> <p>We extracted information from the published papers and by contacting the primary authors of the included papers, where this was possible. Overall results of all the risk of bias assessments are summarised in the <a href="#CD011367-fig-0002">Figure 2</a> and <a href="#CD011367-fig-0003">Figure 3</a> and 'Risk of bias' table. We resolved disagreements between the two review authors. </p> <div class="figure" id="CD011367-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD011367-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011367.pub2/media/CDSR/CD011367/image_n/nCD011367-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD011367-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011367-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011367.pub2/media/CDSR/CD011367/image_n/nCD011367-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD011367-sec-0075"> <h4 class="title">Allocation</h4> <section id="CD011367-sec-0076"> <h5 class="title">Random sequence generation</h5> <p>All three studies were described as RCTs (<a href="./references#CD011367-bbs2-0001" title="ChenD‐M , LiS‐N . The clinical observation of high dose immunoglobulin for children viral encephalitis. Chinese Journal of Primary Medicine and Pharmacy2006;13(5):816‐7. ">Chen 2006</a>; <a href="./references#CD011367-bbs2-0002" title="RayamajhiA , NightingaleS , BhattaNK , SinghR , LedgerE , BistaKP , et al. A preliminary randomized double blind placebo‐controlled trial of intravenous immunoglobulin for Japanese encephalitis in Nepal. PloS One2015;10(4):e0122608. ">Rayamajhi 2015</a>; <a href="./references#CD011367-bbs2-0003" title="WuH , WanZ , LiuL , QiuL , XiulingD . Comparison of the clinical efficacy of immunoglobulin and interferon in the treatment of hand foot and mouth disease complicated with viral encephalitis. Chinese Journal of Primary Medicine and Pharmacy2014;21:3127‐8. ">Wu 2014</a>). However only two of these described the method of randomisation used, which we judged appropriate (<a href="./references#CD011367-bbs2-0002" title="RayamajhiA , NightingaleS , BhattaNK , SinghR , LedgerE , BistaKP , et al. A preliminary randomized double blind placebo‐controlled trial of intravenous immunoglobulin for Japanese encephalitis in Nepal. PloS One2015;10(4):e0122608. ">Rayamajhi 2015</a>; <a href="./references#CD011367-bbs2-0003" title="WuH , WanZ , LiuL , QiuL , XiulingD . Comparison of the clinical efficacy of immunoglobulin and interferon in the treatment of hand foot and mouth disease complicated with viral encephalitis. Chinese Journal of Primary Medicine and Pharmacy2014;21:3127‐8. ">Wu 2014</a>). We judged the risk of selection bias for both studies as low. We judged the risk of selection bias for <a href="./references#CD011367-bbs2-0001" title="ChenD‐M , LiS‐N . The clinical observation of high dose immunoglobulin for children viral encephalitis. Chinese Journal of Primary Medicine and Pharmacy2006;13(5):816‐7. ">Chen 2006</a> as unclear since the exact method of randomisation was not reported. </p> </section> <section id="CD011367-sec-0077"> <h5 class="title">Allocation concealment</h5> <p>Only one study reported the method of allocation concealment (<a href="./references#CD011367-bbs2-0002" title="RayamajhiA , NightingaleS , BhattaNK , SinghR , LedgerE , BistaKP , et al. A preliminary randomized double blind placebo‐controlled trial of intravenous immunoglobulin for Japanese encephalitis in Nepal. PloS One2015;10(4):e0122608. ">Rayamajhi 2015</a>). The randomisation code for each participant in the study was kept in a sealed envelope and was opened by independent investigators. Technicians who were not otherwise connected to the study opened the envelopes containing participant allocation, drew up the study drug, and covered the syringe in opaque tape (because of the subtle differences in colour and viscosity of IVIG and 0.9% saline) before giving it to the nurses for administration. It was unclear whether masking was also applied to the infusion equipment. In addition, empty vials of the study drug were concealed in paper bags. We judged this to be adequate and therefore gave a grade of low risk of bias. We gave two studies a grade of unclear risk of bias for method of allocation concealment since this information was not provided (<a href="./references#CD011367-bbs2-0001" title="ChenD‐M , LiS‐N . The clinical observation of high dose immunoglobulin for children viral encephalitis. Chinese Journal of Primary Medicine and Pharmacy2006;13(5):816‐7. ">Chen 2006</a>; <a href="./references#CD011367-bbs2-0003" title="WuH , WanZ , LiuL , QiuL , XiulingD . Comparison of the clinical efficacy of immunoglobulin and interferon in the treatment of hand foot and mouth disease complicated with viral encephalitis. Chinese Journal of Primary Medicine and Pharmacy2014;21:3127‐8. ">Wu 2014</a>). </p> </section> </section> <section id="CD011367-sec-0078"> <h4 class="title">Blinding</h4> <p><a href="./references#CD011367-bbs2-0002" title="RayamajhiA , NightingaleS , BhattaNK , SinghR , LedgerE , BistaKP , et al. A preliminary randomized double blind placebo‐controlled trial of intravenous immunoglobulin for Japanese encephalitis in Nepal. PloS One2015;10(4):e0122608. ">Rayamajhi 2015</a> was described as a double‐blind study. All investigators, care providers, and participants were blind to the treatment allocation. However, it is unclear whether the investigators who performed the outcome assessment were also blind to the treatment allocation. Therefore, we rated this study at low risk for performance bias and unclear risk for detection bias. Neither of the other two studies gave information on blinding and we judged the risk of performance and detection bias for both studies to be unclear (<a href="./references#CD011367-bbs2-0001" title="ChenD‐M , LiS‐N . The clinical observation of high dose immunoglobulin for children viral encephalitis. Chinese Journal of Primary Medicine and Pharmacy2006;13(5):816‐7. ">Chen 2006</a>; <a href="./references#CD011367-bbs2-0003" title="WuH , WanZ , LiuL , QiuL , XiulingD . Comparison of the clinical efficacy of immunoglobulin and interferon in the treatment of hand foot and mouth disease complicated with viral encephalitis. Chinese Journal of Primary Medicine and Pharmacy2014;21:3127‐8. ">Wu 2014</a>). </p> </section> <section id="CD011367-sec-0079"> <h4 class="title">Incomplete outcome data</h4> <p>Only one study followed up participants beyond the hospitalisation period (<a href="./references#CD011367-bbs2-0002" title="RayamajhiA , NightingaleS , BhattaNK , SinghR , LedgerE , BistaKP , et al. A preliminary randomized double blind placebo‐controlled trial of intravenous immunoglobulin for Japanese encephalitis in Nepal. PloS One2015;10(4):e0122608. ">Rayamajhi 2015</a>). The number of participants lost to follow‐up in each group was carefully reported in using a flow chart and this was equal for both study groups. Fewer participants in the IVIG group compared with the placebo group were included in the assessment of the additional outcomes of the study: difference in anti‐JEV neutralising antibody titres and cytokine abundance and the reason for missing data was clearly provided. Therefore, we rated the risk of attrition bias for <a href="./references#CD011367-bbs2-0002" title="RayamajhiA , NightingaleS , BhattaNK , SinghR , LedgerE , BistaKP , et al. A preliminary randomized double blind placebo‐controlled trial of intravenous immunoglobulin for Japanese encephalitis in Nepal. PloS One2015;10(4):e0122608. ">Rayamajhi 2015</a> as low. Review of data presented in <a href="./references#CD011367-bbs2-0001" title="ChenD‐M , LiS‐N . The clinical observation of high dose immunoglobulin for children viral encephalitis. Chinese Journal of Primary Medicine and Pharmacy2006;13(5):816‐7. ">Chen 2006</a> and <a href="./references#CD011367-bbs2-0003" title="WuH , WanZ , LiuL , QiuL , XiulingD . Comparison of the clinical efficacy of immunoglobulin and interferon in the treatment of hand foot and mouth disease complicated with viral encephalitis. Chinese Journal of Primary Medicine and Pharmacy2014;21:3127‐8. ">Wu 2014</a> did not suggest any loss to follow‐up at the time of discharge, thus we rated the risk of attrition bias for both studies as low. </p> </section> <section id="CD011367-sec-0080"> <h4 class="title">Selective reporting</h4> <p>All three studies identified clinically relevant outcomes (<a href="./references#CD011367-bbs2-0001" title="ChenD‐M , LiS‐N . The clinical observation of high dose immunoglobulin for children viral encephalitis. Chinese Journal of Primary Medicine and Pharmacy2006;13(5):816‐7. ">Chen 2006</a>; <a href="./references#CD011367-bbs2-0002" title="RayamajhiA , NightingaleS , BhattaNK , SinghR , LedgerE , BistaKP , et al. A preliminary randomized double blind placebo‐controlled trial of intravenous immunoglobulin for Japanese encephalitis in Nepal. PloS One2015;10(4):e0122608. ">Rayamajhi 2015</a>; <a href="./references#CD011367-bbs2-0003" title="WuH , WanZ , LiuL , QiuL , XiulingD . Comparison of the clinical efficacy of immunoglobulin and interferon in the treatment of hand foot and mouth disease complicated with viral encephalitis. Chinese Journal of Primary Medicine and Pharmacy2014;21:3127‐8. ">Wu 2014</a>). However, only one study reported on outcomes beyond the hospitalisation period (<a href="./references#CD011367-bbs2-0002" title="RayamajhiA , NightingaleS , BhattaNK , SinghR , LedgerE , BistaKP , et al. A preliminary randomized double blind placebo‐controlled trial of intravenous immunoglobulin for Japanese encephalitis in Nepal. PloS One2015;10(4):e0122608. ">Rayamajhi 2015</a>). Only one study reported on neurological outcomes (<a href="./references#CD011367-bbs2-0002" title="RayamajhiA , NightingaleS , BhattaNK , SinghR , LedgerE , BistaKP , et al. A preliminary randomized double blind placebo‐controlled trial of intravenous immunoglobulin for Japanese encephalitis in Nepal. PloS One2015;10(4):e0122608. ">Rayamajhi 2015</a>), which are of crucial clinical relevance in encephalitis with only one study using a validated assessment scale for assessment of this outcome (<a href="./references#CD011367-bbs2-0002" title="RayamajhiA , NightingaleS , BhattaNK , SinghR , LedgerE , BistaKP , et al. A preliminary randomized double blind placebo‐controlled trial of intravenous immunoglobulin for Japanese encephalitis in Nepal. PloS One2015;10(4):e0122608. ">Rayamajhi 2015</a>). We identified the protocol for only one of the included studies (<a href="./references#CD011367-bbs2-0002" title="RayamajhiA , NightingaleS , BhattaNK , SinghR , LedgerE , BistaKP , et al. A preliminary randomized double blind placebo‐controlled trial of intravenous immunoglobulin for Japanese encephalitis in Nepal. PloS One2015;10(4):e0122608. ">Rayamajhi 2015</a>) and some a priori identified endpoints were not reported. Details of participant death were also only provided for the IVIG and not the placebo group. Therefore, we rated the risk of reporting bias as high. The protocols for the other included studies were not publicly available thus we were unable to check whether all predefined outcomes were reported (<a href="./references#CD011367-bbs2-0001" title="ChenD‐M , LiS‐N . The clinical observation of high dose immunoglobulin for children viral encephalitis. Chinese Journal of Primary Medicine and Pharmacy2006;13(5):816‐7. ">Chen 2006</a>; <a href="./references#CD011367-bbs2-0003" title="WuH , WanZ , LiuL , QiuL , XiulingD . Comparison of the clinical efficacy of immunoglobulin and interferon in the treatment of hand foot and mouth disease complicated with viral encephalitis. Chinese Journal of Primary Medicine and Pharmacy2014;21:3127‐8. ">Wu 2014</a>). Therefore, we rated the risk of reporting bias for the two studies as unclear. </p> </section> <section id="CD011367-sec-0081"> <h4 class="title">Other potential sources of bias</h4> <p>The sample size for <a href="./references#CD011367-bbs2-0002" title="RayamajhiA , NightingaleS , BhattaNK , SinghR , LedgerE , BistaKP , et al. A preliminary randomized double blind placebo‐controlled trial of intravenous immunoglobulin for Japanese encephalitis in Nepal. PloS One2015;10(4):e0122608. ">Rayamajhi 2015</a> was calculated to detect differences in the study groups for a tertiary outcome. Therefore, it is unclear whether the study was adequately powered to detect any differences between the study groups for either the primary or secondary outcomes. There was some discrepancy in the reported recruitment period. Key information such as the split in the number of participants admitted to ICU was not reported, this information is important since admission to ICU is a surrogate for disease severity. There was also an imbalance with the number of participants in both study groups who received corticosteroid therapy, which is a potential confounder and this was not considered in the analysis. The main authors' group provided funding for the study hence conflict of interests could not be excluded. Therefore, we rated <a href="./references#CD011367-bbs2-0002" title="RayamajhiA , NightingaleS , BhattaNK , SinghR , LedgerE , BistaKP , et al. A preliminary randomized double blind placebo‐controlled trial of intravenous immunoglobulin for Japanese encephalitis in Nepal. PloS One2015;10(4):e0122608. ">Rayamajhi 2015</a> as having high risk for other bias. The sample sizes for <a href="./references#CD011367-bbs2-0001" title="ChenD‐M , LiS‐N . The clinical observation of high dose immunoglobulin for children viral encephalitis. Chinese Journal of Primary Medicine and Pharmacy2006;13(5):816‐7. ">Chen 2006</a> and <a href="./references#CD011367-bbs2-0003" title="WuH , WanZ , LiuL , QiuL , XiulingD . Comparison of the clinical efficacy of immunoglobulin and interferon in the treatment of hand foot and mouth disease complicated with viral encephalitis. Chinese Journal of Primary Medicine and Pharmacy2014;21:3127‐8. ">Wu 2014</a> were small and information on sample size calculation for both studies was not provided. Therefore, it is unclear whether these studies were sufficiently powered to detect differences between the study groups. Also, no funding information was provided for both studies. Specific information on the eligibility criteria used to identify participants in <a href="./references#CD011367-bbs2-0003" title="WuH , WanZ , LiuL , QiuL , XiulingD . Comparison of the clinical efficacy of immunoglobulin and interferon in the treatment of hand foot and mouth disease complicated with viral encephalitis. Chinese Journal of Primary Medicine and Pharmacy2014;21:3127‐8. ">Wu 2014</a> was not provided which makes it impossible to ascertain how well the study population truly represents children with viral encephalitis. Therefore, we judged the risk of other bias for both studies as unclear (<a href="./references#CD011367-bbs2-0001" title="ChenD‐M , LiS‐N . The clinical observation of high dose immunoglobulin for children viral encephalitis. Chinese Journal of Primary Medicine and Pharmacy2006;13(5):816‐7. ">Chen 2006</a>; <a href="./references#CD011367-bbs2-0003" title="WuH , WanZ , LiuL , QiuL , XiulingD . Comparison of the clinical efficacy of immunoglobulin and interferon in the treatment of hand foot and mouth disease complicated with viral encephalitis. Chinese Journal of Primary Medicine and Pharmacy2014;21:3127‐8. ">Wu 2014</a>). Due to the limited number of included studies (fewer than 10), we were unable to investigate potential publication bias using a funnel plot. </p> <section id="CD011367-sec-0082"> <h5 class="title">Risk of bias for adverse events</h5> <p>Based on our predefined criteria, we rated <a href="./references#CD011367-bbs2-0002" title="RayamajhiA , NightingaleS , BhattaNK , SinghR , LedgerE , BistaKP , et al. A preliminary randomized double blind placebo‐controlled trial of intravenous immunoglobulin for Japanese encephalitis in Nepal. PloS One2015;10(4):e0122608. ">Rayamajhi 2015</a> as having a low risk of bias for adverse events and the other two studies as having unclear risk of bias (<a href="./references#CD011367-bbs2-0001" title="ChenD‐M , LiS‐N . The clinical observation of high dose immunoglobulin for children viral encephalitis. Chinese Journal of Primary Medicine and Pharmacy2006;13(5):816‐7. ">Chen 2006</a>; <a href="./references#CD011367-bbs2-0003" title="WuH , WanZ , LiuL , QiuL , XiulingD . Comparison of the clinical efficacy of immunoglobulin and interferon in the treatment of hand foot and mouth disease complicated with viral encephalitis. Chinese Journal of Primary Medicine and Pharmacy2014;21:3127‐8. ">Wu 2014</a>). Further information is provided in <a href="#CD011367-tbl-0002">Table 1</a>. </p> <div class="table" id="CD011367-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Risk of bias (adverse events)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Risk of bias</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Did the researchers actively monitor for AEs or did they simply provide spontaneous reporting of AEs that arose?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Risk of bias</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Did the authors define SAEs according to an accepted international classification and report the number of SAEs?</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011367-bbs2-0001" title="ChenD‐M , LiS‐N . The clinical observation of high dose immunoglobulin for children viral encephalitis. Chinese Journal of Primary Medicine and Pharmacy2006;13(5):816‐7. ">Chen 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Information not provided.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Information not provided.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011367-bbs2-0002" title="RayamajhiA , NightingaleS , BhattaNK , SinghR , LedgerE , BistaKP , et al. A preliminary randomized double blind placebo‐controlled trial of intravenous immunoglobulin for Japanese encephalitis in Nepal. PloS One2015;10(4):e0122608. ">Rayamajhi 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The authors reported that participants were monitored for AEs from first day of commencing treatment until death or discharge </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AEs graded using WHO recommendations and reported to an independent data safety monitoring committee. Information recorded on standardised proformas. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011367-bbs2-0003" title="WuH , WanZ , LiuL , QiuL , XiulingD . Comparison of the clinical efficacy of immunoglobulin and interferon in the treatment of hand foot and mouth disease complicated with viral encephalitis. Chinese Journal of Primary Medicine and Pharmacy2014;21:3127‐8. ">Wu 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Information not provided.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Information not provided.</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>AE: adverse events; SAE: serious adverse events; WHO: World Health Organisation.</p> </div> </div> </section> </section> </section> <section id="CD011367-sec-0083"> <h3 class="title" id="CD011367-sec-0083">Effects of interventions</h3> <p>See: <a href="./full#CD011367-tbl-0001"><b>Summary of findings for the main comparison</b> Intravenous immunoglobulin with or without standard care compared with standard care alone or placebo for children with acute encephalitis</a> </p> <section id="CD011367-sec-0084"> <h4 class="title">Primary outcomes</h4> <section id="CD011367-sec-0085"> <h5 class="title">Proportion of participants with significant disability (= 'poor outcome') assessed at six months after treatment </h5> <p>Only one study reported proportion of participants with significant disability (<a href="./references#CD011367-bbs2-0002" title="RayamajhiA , NightingaleS , BhattaNK , SinghR , LedgerE , BistaKP , et al. A preliminary randomized double blind placebo‐controlled trial of intravenous immunoglobulin for Japanese encephalitis in Nepal. PloS One2015;10(4):e0122608. ">Rayamajhi 2015</a>). <a href="./references#CD011367-bbs2-0002" title="RayamajhiA , NightingaleS , BhattaNK , SinghR , LedgerE , BistaKP , et al. A preliminary randomized double blind placebo‐controlled trial of intravenous immunoglobulin for Japanese encephalitis in Nepal. PloS One2015;10(4):e0122608. ">Rayamajhi 2015</a> assessed disability at three to six months' follow‐up using a validated assessment tool, the Liverpool Outcome Score. Based on the predefined definitions for this review (significant disability = Liverpool Outcome Score of 2 or less), 3/11 (27.3%) participants in the IVIG group versus 4/11 (36.4%) participants in the placebo group had significant disability at three to six months (RR 0.75, 95% CI 0.22 to 2.60; P = 0.65) (<a href="./references#CD011367-fig-0004" title="">Analysis 1.1</a>). </p> </section> <section id="CD011367-sec-0086"> <h5 class="title">Proportion of participants with at least one serious adverse event</h5> <p>All three studies reported on adverse events. Only one study provided information on the criteria used to categorise adverse events where adverse events were graded using the WHO recommendations (<a href="./references#CD011367-bbs2-0002" title="RayamajhiA , NightingaleS , BhattaNK , SinghR , LedgerE , BistaKP , et al. A preliminary randomized double blind placebo‐controlled trial of intravenous immunoglobulin for Japanese encephalitis in Nepal. PloS One2015;10(4):e0122608. ">Rayamajhi 2015</a>). Reported serious adverse events included death, melaena, and hypotension. For the other included studies for which a clear definition of serious adverse event was not provided (<a href="./references#CD011367-bbs2-0001" title="ChenD‐M , LiS‐N . The clinical observation of high dose immunoglobulin for children viral encephalitis. Chinese Journal of Primary Medicine and Pharmacy2006;13(5):816‐7. ">Chen 2006</a>; <a href="./references#CD011367-bbs2-0003" title="WuH , WanZ , LiuL , QiuL , XiulingD . Comparison of the clinical efficacy of immunoglobulin and interferon in the treatment of hand foot and mouth disease complicated with viral encephalitis. Chinese Journal of Primary Medicine and Pharmacy2014;21:3127‐8. ">Wu 2014</a>), we used the ICH Tripartite Guideline to determine which reported adverse events were serious, based on available information reported in the paper. Adverse events reported by <a href="./references#CD011367-bbs2-0001" title="ChenD‐M , LiS‐N . The clinical observation of high dose immunoglobulin for children viral encephalitis. Chinese Journal of Primary Medicine and Pharmacy2006;13(5):816‐7. ">Chen 2006</a> included flushing and itchy skin while <a href="./references#CD011367-bbs2-0003" title="WuH , WanZ , LiuL , QiuL , XiulingD . Comparison of the clinical efficacy of immunoglobulin and interferon in the treatment of hand foot and mouth disease complicated with viral encephalitis. Chinese Journal of Primary Medicine and Pharmacy2014;21:3127‐8. ">Wu 2014</a> reported on nausea, palpitations, and chest tightness. We did not consider any of these adverse events to meet the serious adverse event criteria. Therefore, information on serious adverse events was only available from one study (<a href="./references#CD011367-bbs2-0002" title="RayamajhiA , NightingaleS , BhattaNK , SinghR , LedgerE , BistaKP , et al. A preliminary randomized double blind placebo‐controlled trial of intravenous immunoglobulin for Japanese encephalitis in Nepal. PloS One2015;10(4):e0122608. ">Rayamajhi 2015</a>). The number of participants experiencing at least one significant adverse event was 1/11 in the IVIG group and 1/11 in the placebo group (RR 1.00, 95% CI 0.07 to 14.05; P = 1.00) (<a href="./references#CD011367-fig-0005" title="">Analysis 2.1</a>). In <a href="./references#CD011367-bbs2-0002" title="RayamajhiA , NightingaleS , BhattaNK , SinghR , LedgerE , BistaKP , et al. A preliminary randomized double blind placebo‐controlled trial of intravenous immunoglobulin for Japanese encephalitis in Nepal. PloS One2015;10(4):e0122608. ">Rayamajhi 2015</a>, the proportion of deaths in the IVIG group was 1/11 versus 2/11 in the placebo group (RR 0.50, 95% CI 0.05 to 4.75; P = 0.55) (<a href="./references#CD011367-fig-0006" title="">Analysis 2.2</a>). <a href="./references#CD011367-bbs2-0002" title="RayamajhiA , NightingaleS , BhattaNK , SinghR , LedgerE , BistaKP , et al. A preliminary randomized double blind placebo‐controlled trial of intravenous immunoglobulin for Japanese encephalitis in Nepal. PloS One2015;10(4):e0122608. ">Rayamajhi 2015</a> reported no significant difference in the number of participants experiencing either hypotension or melaena in either group (RR 1.00, 95% CI 0.07 to 14.05; P = 1.00) (<a href="./references#CD011367-fig-0007" title="">Analysis 2.3</a>; <a href="./references#CD011367-fig-0008" title="">Analysis 2.4</a>). </p> </section> </section> <section id="CD011367-sec-0087"> <h4 class="title">Secondary outcomes</h4> <section id="CD011367-sec-0088"> <h5 class="title">Proportion of participants with significant disability at discharge</h5> <p>Only one of the included studies assessed disability at the time of discharge and reported 8/11 participants in each group as having significant disability at discharge (RR 1.00, 95% CI 0.60 to 1.67; P = 1.00). (<a href="./references#CD011367-fig-0009" title="">Analysis 3.1</a>) (<a href="./references#CD011367-bbs2-0002" title="RayamajhiA , NightingaleS , BhattaNK , SinghR , LedgerE , BistaKP , et al. A preliminary randomized double blind placebo‐controlled trial of intravenous immunoglobulin for Japanese encephalitis in Nepal. PloS One2015;10(4):e0122608. ">Rayamajhi 2015</a>). </p> </section> <section id="CD011367-sec-0089"> <h5 class="title">Glasgow Coma Score at discharge</h5> <p>Only one included study assessed Glasgow Coma Score at discharge and reported a no significant difference between the IVIG and placebo groups (IVIG: median score 14, range 3 to 15; placebo: median score 14, range 7‐15; P = 0.53) (<a href="./references#CD011367-bbs2-0002" title="RayamajhiA , NightingaleS , BhattaNK , SinghR , LedgerE , BistaKP , et al. A preliminary randomized double blind placebo‐controlled trial of intravenous immunoglobulin for Japanese encephalitis in Nepal. PloS One2015;10(4):e0122608. ">Rayamajhi 2015</a>). </p> </section> <section id="CD011367-sec-0090"> <h5 class="title">Length of hospital stay</h5> <p>All three studies reported length of hospital stay. Two studies reported length of stay as mean and SDs (<a href="./references#CD011367-bbs2-0001" title="ChenD‐M , LiS‐N . The clinical observation of high dose immunoglobulin for children viral encephalitis. Chinese Journal of Primary Medicine and Pharmacy2006;13(5):816‐7. ">Chen 2006</a>; <a href="./references#CD011367-bbs2-0003" title="WuH , WanZ , LiuL , QiuL , XiulingD . Comparison of the clinical efficacy of immunoglobulin and interferon in the treatment of hand foot and mouth disease complicated with viral encephalitis. Chinese Journal of Primary Medicine and Pharmacy2014;21:3127‐8. ">Wu 2014</a>), while one study reported length of hospital stay as median and range (<a href="./references#CD011367-bbs2-0002" title="RayamajhiA , NightingaleS , BhattaNK , SinghR , LedgerE , BistaKP , et al. A preliminary randomized double blind placebo‐controlled trial of intravenous immunoglobulin for Japanese encephalitis in Nepal. PloS One2015;10(4):e0122608. ">Rayamajhi 2015</a>). Pooled analysis of two studies found a significant difference in favour of the IVIG group (MD ‐4.54 days, 95% CI ‐7.47 to ‐1.61; P = 0.002) (<a href="./references#CD011367-fig-0010" title="">Analysis 4.1</a>) (<a href="./references#CD011367-bbs2-0001" title="ChenD‐M , LiS‐N . The clinical observation of high dose immunoglobulin for children viral encephalitis. Chinese Journal of Primary Medicine and Pharmacy2006;13(5):816‐7. ">Chen 2006</a>; <a href="./references#CD011367-bbs2-0003" title="WuH , WanZ , LiuL , QiuL , XiulingD . Comparison of the clinical efficacy of immunoglobulin and interferon in the treatment of hand foot and mouth disease complicated with viral encephalitis. Chinese Journal of Primary Medicine and Pharmacy2014;21:3127‐8. ">Wu 2014</a>). <a href="./references#CD011367-bbs2-0002" title="RayamajhiA , NightingaleS , BhattaNK , SinghR , LedgerE , BistaKP , et al. A preliminary randomized double blind placebo‐controlled trial of intravenous immunoglobulin for Japanese encephalitis in Nepal. PloS One2015;10(4):e0122608. ">Rayamajhi 2015</a> found no significant difference between groups (IVIG: median 13 days; range 9 to 21; placebo: median 12 days; range 6 to 18; P value 0.59). <a href="./references#CD011367-bbs2-0003" title="WuH , WanZ , LiuL , QiuL , XiulingD . Comparison of the clinical efficacy of immunoglobulin and interferon in the treatment of hand foot and mouth disease complicated with viral encephalitis. Chinese Journal of Primary Medicine and Pharmacy2014;21:3127‐8. ">Wu 2014</a> also compared mean length of stay between participants receiving IVIG or interferon in addition to standard care and reported a significant difference in favour of IVIG (MD ‐0.57, 95% CI ‐0.99 to ‐0.15; P = 0.008) (<a href="./references#CD011367-fig-0011" title="">Analysis 4.2</a>). </p> </section> <section id="CD011367-sec-0091"> <h5 class="title">Proportion of participants requiring invasive ventilation and duration</h5> <p>None of the included studies reported the proportion of participants requiring invasive ventilation and duration of ventilation. </p> </section> <section id="CD011367-sec-0092"> <h5 class="title">Time to fever resolution</h5> <p>Two of the included studies reported on days to fever resolution as mean and SDs (<a href="./references#CD011367-bbs2-0001" title="ChenD‐M , LiS‐N . The clinical observation of high dose immunoglobulin for children viral encephalitis. Chinese Journal of Primary Medicine and Pharmacy2006;13(5):816‐7. ">Chen 2006</a>; <a href="./references#CD011367-bbs2-0003" title="WuH , WanZ , LiuL , QiuL , XiulingD . Comparison of the clinical efficacy of immunoglobulin and interferon in the treatment of hand foot and mouth disease complicated with viral encephalitis. Chinese Journal of Primary Medicine and Pharmacy2014;21:3127‐8. ">Wu 2014</a>). Pooled analysis showed a significant difference in favour of IVIG (MD ‐0.97 days, 95% CI ‐1.25 to ‐0.69; P &lt; 0.00001) (<a href="./references#CD011367-fig-0012" title="">Analysis 5.1</a>). <a href="./references#CD011367-bbs2-0003" title="WuH , WanZ , LiuL , QiuL , XiulingD . Comparison of the clinical efficacy of immunoglobulin and interferon in the treatment of hand foot and mouth disease complicated with viral encephalitis. Chinese Journal of Primary Medicine and Pharmacy2014;21:3127‐8. ">Wu 2014</a> also compared days to fever resolution between participants receiving IVIG or interferon in addition to standard care and reported a statistically significant difference in favour of IVIG (MD ‐0.27 days, 95% CI ‐0.42 to ‐0.12; P = 0.0006) (<a href="./references#CD011367-fig-0013" title="">Analysis 5.2</a>). </p> </section> <section id="CD011367-sec-0093"> <h5 class="title">Time to stop spasms</h5> <p>Two of the included studies reported on days to stop convulsions/spasms as mean and SDs (<a href="./references#CD011367-bbs2-0001" title="ChenD‐M , LiS‐N . The clinical observation of high dose immunoglobulin for children viral encephalitis. Chinese Journal of Primary Medicine and Pharmacy2006;13(5):816‐7. ">Chen 2006</a>; <a href="./references#CD011367-bbs2-0003" title="WuH , WanZ , LiuL , QiuL , XiulingD . Comparison of the clinical efficacy of immunoglobulin and interferon in the treatment of hand foot and mouth disease complicated with viral encephalitis. Chinese Journal of Primary Medicine and Pharmacy2014;21:3127‐8. ">Wu 2014</a>). Pooled analysis showed a significant difference in favour of IVIG (MD ‐1.49 days, 95% CI ‐1.97 to ‐1.01; P &lt; 0.00001) (<a href="./references#CD011367-fig-0014" title="">Analysis 6.1</a>). <a href="./references#CD011367-bbs2-0003" title="WuH , WanZ , LiuL , QiuL , XiulingD . Comparison of the clinical efficacy of immunoglobulin and interferon in the treatment of hand foot and mouth disease complicated with viral encephalitis. Chinese Journal of Primary Medicine and Pharmacy2014;21:3127‐8. ">Wu 2014</a> also compared time to stop spasms between the IVIG and interferon group and reported no significant difference between groups (MD ‐0.17, 95% CI ‐0.34 to 0.00; P = 0.06) (<a href="./references#CD011367-fig-0015" title="">Analysis 6.2</a>). </p> </section> <section id="CD011367-sec-0094"> <h5 class="title">Time to regain consciousness</h5> <p>Only one study reported time to regain consciousness as mean and SDs and found a statistically significant difference in favour of the IVIG group (MD ‐1.10, 95% CI ‐1.48 to ‐0.72; P &lt; 0.00001) (<a href="./references#CD011367-fig-0016" title="">Analysis 7.1</a>) (<a href="./references#CD011367-bbs2-0001" title="ChenD‐M , LiS‐N . The clinical observation of high dose immunoglobulin for children viral encephalitis. Chinese Journal of Primary Medicine and Pharmacy2006;13(5):816‐7. ">Chen 2006</a>). </p> </section> <section id="CD011367-sec-0095"> <h5 class="title">Time to resolution of neuropathic symptoms</h5> <p><a href="./references#CD011367-bbs2-0003" title="WuH , WanZ , LiuL , QiuL , XiulingD . Comparison of the clinical efficacy of immunoglobulin and interferon in the treatment of hand foot and mouth disease complicated with viral encephalitis. Chinese Journal of Primary Medicine and Pharmacy2014;21:3127‐8. ">Wu 2014</a> reported time to resolution of neuropathic symptoms as mean and SDs and found a statistically significant difference in favour of the IVIG group when compared with standard care (MD ‐3.20 days, 95% CI ‐3.34 to ‐3.06; P &lt; 0.00001) (<a href="./references#CD011367-fig-0017" title="">Analysis 8.1</a>). There was a statistically significant difference in favour of the IVIG group when compared with interferon (MD ‐0.49 days, 95% CI ‐0.70 to ‐0.28; P &lt; 0.00001) (<a href="./references#CD011367-fig-0018" title="">Analysis 8.2</a>). </p> </section> <section id="CD011367-sec-0096"> <h5 class="title">Cognitive impairment</h5> <p>None of the included studies reported cognitive impairment.</p> </section> <section id="CD011367-sec-0097"> <h5 class="title">Poor adaptive functioning</h5> <p>None of the included studies reported poor adaptive functioning.</p> </section> <section id="CD011367-sec-0098"> <h5 class="title">Quality of life assessment</h5> <p>None of the included studies reported quality of life.</p> </section> <section id="CD011367-sec-0099"> <h5 class="title">Number of seizures and proportion of participants with new diagnosis of epilepsy</h5> <p>None of the included studies reported number of seizures and proportion of participants with new diagnosis of epilepsy. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD011367-sec-0100" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD011367-sec-0100"></div> <section id="CD011367-sec-0101"> <h3 class="title" id="CD011367-sec-0101">Summary of main results</h3> <p>The purpose of this review was to evaluate whether treatment with IVIG in addition to standard care for children with encephalitis was different in terms of efficacy and safety when compared with standard care alone or placebo. We did this by performing a systematic review of RCTs reporting head‐to‐head comparison of these treatments. Three RCTs involving 138 participants (70 participants treated with IVIG either alone or in addition to standard care and 68 participants treated with either standard care or placebo) were included and contributed to this review data. However, not all the included studies contributed to the data for the different outcomes assessed with only 22 participants (11 participants in each group) from one study of Japanese encephalitis (<a href="./references#CD011367-bbs2-0002" title="RayamajhiA , NightingaleS , BhattaNK , SinghR , LedgerE , BistaKP , et al. A preliminary randomized double blind placebo‐controlled trial of intravenous immunoglobulin for Japanese encephalitis in Nepal. PloS One2015;10(4):e0122608. ">Rayamajhi 2015</a>) contributing to the primary outcomes of this review. Only one study followed up participants beyond hospital discharge, for three to six months (<a href="./references#CD011367-bbs2-0002" title="RayamajhiA , NightingaleS , BhattaNK , SinghR , LedgerE , BistaKP , et al. A preliminary randomized double blind placebo‐controlled trial of intravenous immunoglobulin for Japanese encephalitis in Nepal. PloS One2015;10(4):e0122608. ">Rayamajhi 2015</a>). </p> <p>The main conclusion based on the findings of one study in children with Japanese encephalitis was that IVIG treatment did not offer additional benefit over placebo when clinical efficacy (proportion of participants with significant disability) and safety (proportion of participants with at least one serious adverse event) were considered. Similarly, the median length of hospital stay and Glasgow Coma Score at the time of hospital discharge were similar for children with Japanese encephalitis who received IVIG treatment and those who received placebo. Based on the findings of two other studies of viral encephalitis, adjunctive IVIG treatment was more effective than standard care alone in reducing the mean length of hospital stay, time to resolution of spasms, neuropathic symptom, time to regain consciousness, and time to resolution of fever. Methodological issues in the included studies have been highlighted. </p> <p>The quality of evidence was judged as very low (<a href="./full#CD011367-tbl-0001">summary of findings Table for the main comparison</a>). </p> </section> <section id="CD011367-sec-0102"> <h3 class="title" id="CD011367-sec-0102">Overall completeness and applicability of evidence</h3> <p>The studies included in this review were heterogeneous in terms of the type of encephalitis that participants had. None of the studies included participants with non‐viral or immune‐mediated forms of encephalitis. The dose of IVIG used in all three studies was similar. </p> <p>The objective of this review was achieved allowing comparison between IVIG and standard care or placebo in terms of the main clinical efficacy and safety outcomes; however, only one study contributed data to the primary outcome analysis. For this review, we selected outcome measures that are thought to be clinically relevant in encephalitis after consulting with specialists in the field. Several predefined secondary outcomes such as cognitive functioning, adaptive functioning, and quality of life were not reported in the included studies which impaired comparison of these outcomes. Assessment of long‐term outcomes is extremely important in the management of people with encephalitis since up to 60% of affected people can experience long‐term morbidity. Participants were not followed up in two of the included studies (<a href="./references#CD011367-bbs2-0001" title="ChenD‐M , LiS‐N . The clinical observation of high dose immunoglobulin for children viral encephalitis. Chinese Journal of Primary Medicine and Pharmacy2006;13(5):816‐7. ">Chen 2006</a>; <a href="./references#CD011367-bbs2-0003" title="WuH , WanZ , LiuL , QiuL , XiulingD . Comparison of the clinical efficacy of immunoglobulin and interferon in the treatment of hand foot and mouth disease complicated with viral encephalitis. Chinese Journal of Primary Medicine and Pharmacy2014;21:3127‐8. ">Wu 2014</a>), and follow‐up was short (three to six months) in the only study where participants were followed up (<a href="./references#CD011367-bbs2-0002" title="RayamajhiA , NightingaleS , BhattaNK , SinghR , LedgerE , BistaKP , et al. A preliminary randomized double blind placebo‐controlled trial of intravenous immunoglobulin for Japanese encephalitis in Nepal. PloS One2015;10(4):e0122608. ">Rayamajhi 2015</a>). </p> <p>The main limitations of the findings of this review included the small number of identified studies contributing to the meta‐analysis, the small sample size in each of the included studies, the short follow‐up period, and the inherent methodological limitations in each of the included studies which might have a role in the final assessment of efficacy and safety of IVIG treatment. In addition, the quality of evidence was very low for the prespecified outcomes reported in the included studies (<a href="./full#CD011367-tbl-0001">summary of findings Table for the main comparison</a>). Furthermore, there was heterogeneity in terms of the type of encephalitis studied and the eligibility criteria used limits generalisability of the findings. All included studies were conducted in lower middle‐income countries: Nepal (<a href="./references#CD011367-bbs2-0002" title="RayamajhiA , NightingaleS , BhattaNK , SinghR , LedgerE , BistaKP , et al. A preliminary randomized double blind placebo‐controlled trial of intravenous immunoglobulin for Japanese encephalitis in Nepal. PloS One2015;10(4):e0122608. ">Rayamajhi 2015</a>) and China (<a href="./references#CD011367-bbs2-0001" title="ChenD‐M , LiS‐N . The clinical observation of high dose immunoglobulin for children viral encephalitis. Chinese Journal of Primary Medicine and Pharmacy2006;13(5):816‐7. ">Chen 2006</a>; <a href="./references#CD011367-bbs2-0003" title="WuH , WanZ , LiuL , QiuL , XiulingD . Comparison of the clinical efficacy of immunoglobulin and interferon in the treatment of hand foot and mouth disease complicated with viral encephalitis. Chinese Journal of Primary Medicine and Pharmacy2014;21:3127‐8. ">Wu 2014</a>), which further limits the extent to which the findings could be applied to other settings such as high middle‐income countries. Therefore, it is not possible to draw any definite conclusions on the safety and efficacy of IVIG in the treatment of childhood encephalitis from these data. This highlights the need for a well‐designed RCT of a large sample size in which participants are followed up for a longer time and clinically relevant outcomes such as adaptive and cognitive functioning are assessed. The identified ongoing trial looks promising and could be key to addressing the objectives of this review (<a href="./references#CD011367-bbs2-0013" title="NCT02308982 . Investigating the role of early intravenous immunoglobulin treatment for children with encephalitis [A phase III multi‐centre randomised, double blind, placebo controlled trial to assess the role of intravenous immunoglobulin in the management of children with encephalitis]. clinicaltrials.gov/ct2/show/record/NCT02308982 Date first received; 1 December 2014. ">NCT02308982</a>). </p> </section> <section id="CD011367-sec-0103"> <h3 class="title" id="CD011367-sec-0103">Quality of the evidence</h3> <p>We included three RCTs but not all contributed to the analyses for the different outcomes with only one study contributing data for the primary outcome. Where two studies reported on the same efficacy outcome, there was no heterogeneity of results. The body of evidence was judged to be of very low quality (<a href="./full#CD011367-tbl-0001">summary of findings Table for the main comparison</a>). </p> </section> <section id="CD011367-sec-0104"> <h3 class="title" id="CD011367-sec-0104">Potential biases in the review process</h3> <p>The review authors declared no conflicts of interest in this review. We undertook an extensive and comprehensive search to minimise bias in the review process. The trial search strategy and contacts initiated with the main investigators suggested the likelihood that all relevant studies were identified and as far as possible, all relevant data were obtained. Two review authors independently screened trials identified by the search, extracted the data, and assessed the quality of included trials to minimise potential biases. </p> </section> <section id="CD011367-sec-0105"> <h3 class="title" id="CD011367-sec-0105">Agreements and disagreements with other studies or reviews</h3> <p>To our knowledge this is the first meta‐analysis of IVIG treatment for childhood encephalitis published. One recently published systematic review of IVIG use in paediatric neurology and neurodevelopmental disorders concluded that it is possible that IVIG improves recovery in acute disseminated encephalomyelitis and that IVIG with or without additional immunotherapy is associated with significant or full recovery in N‐methyl‐D‐aspartate receptor antibody encephalitis (<a href="./references#CD011367-bbs2-0037" title="GadianJ , KirkE , HollidayK , LimM , AbsoudM . Systematic review of immunoglobulin use in paediatric neurological and neurodevelopmental disorders. Developmental Medicine and Child Neurology2017;59(2):133‐44. ">Gadian 2017</a>). Of note, the conclusions of the review were based on qualitative synthesis without fully considering the potential influences of bias on the internal validity of the results. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD011367-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011367.pub2/media/CDSR/CD011367/urn:x-wiley:14651858:media:CD011367:CD011367-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011367.pub2/media/CDSR/CD011367/image_t/tCD011367-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram. RCT: randomised controlled trial." data-id="CD011367-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011367.pub2/media/CDSR/CD011367/image_n/nCD011367-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram. RCT: randomised controlled trial.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011367.pub2/full#CD011367-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011367.pub2/media/CDSR/CD011367/image_n/nCD011367-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011367-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011367.pub2/media/CDSR/CD011367/urn:x-wiley:14651858:media:CD011367:CD011367-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011367.pub2/media/CDSR/CD011367/image_t/tCD011367-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD011367-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011367.pub2/media/CDSR/CD011367/image_n/nCD011367-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011367.pub2/full#CD011367-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011367.pub2/media/CDSR/CD011367/image_n/nCD011367-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011367-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011367.pub2/media/CDSR/CD011367/urn:x-wiley:14651858:media:CD011367:CD011367-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011367.pub2/media/CDSR/CD011367/image_t/tCD011367-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011367-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011367.pub2/media/CDSR/CD011367/image_n/nCD011367-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011367.pub2/full#CD011367-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011367.pub2/media/CDSR/CD011367/image_n/nCD011367-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011367-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011367.pub2/media/CDSR/CD011367/urn:x-wiley:14651858:media:CD011367:CD011367-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011367.pub2/media/CDSR/CD011367/image_t/tCD011367-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Significant disability at six months, Outcome 1 Significant disability at 3‐6 months." data-id="CD011367-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011367.pub2/media/CDSR/CD011367/image_n/nCD011367-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Significant disability at six months, Outcome 1 Significant disability at 3‐6 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011367.pub2/references#CD011367-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011367.pub2/media/CDSR/CD011367/image_n/nCD011367-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011367-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011367.pub2/media/CDSR/CD011367/urn:x-wiley:14651858:media:CD011367:CD011367-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011367.pub2/media/CDSR/CD011367/image_t/tCD011367-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Serious adverse events, Outcome 1 ≥ 1 serious adverse event." data-id="CD011367-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011367.pub2/media/CDSR/CD011367/image_n/nCD011367-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Serious adverse events, Outcome 1 ≥ 1 serious adverse event.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011367.pub2/references#CD011367-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011367.pub2/media/CDSR/CD011367/image_n/nCD011367-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011367-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011367.pub2/media/CDSR/CD011367/urn:x-wiley:14651858:media:CD011367:CD011367-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011367.pub2/media/CDSR/CD011367/image_t/tCD011367-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Serious adverse events, Outcome 2 Mortality." data-id="CD011367-fig-0006" src="/cdsr/doi/10.1002/14651858.CD011367.pub2/media/CDSR/CD011367/image_n/nCD011367-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Serious adverse events, Outcome 2 Mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011367.pub2/references#CD011367-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011367.pub2/media/CDSR/CD011367/image_n/nCD011367-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011367-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011367.pub2/media/CDSR/CD011367/urn:x-wiley:14651858:media:CD011367:CD011367-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011367.pub2/media/CDSR/CD011367/image_t/tCD011367-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Serious adverse events, Outcome 3 Hypotension." data-id="CD011367-fig-0007" src="/cdsr/doi/10.1002/14651858.CD011367.pub2/media/CDSR/CD011367/image_n/nCD011367-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Serious adverse events, Outcome 3 Hypotension.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011367.pub2/references#CD011367-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011367.pub2/media/CDSR/CD011367/image_n/nCD011367-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011367-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011367.pub2/media/CDSR/CD011367/urn:x-wiley:14651858:media:CD011367:CD011367-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011367.pub2/media/CDSR/CD011367/image_t/tCD011367-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Serious adverse events, Outcome 4 Melaena." data-id="CD011367-fig-0008" src="/cdsr/doi/10.1002/14651858.CD011367.pub2/media/CDSR/CD011367/image_n/nCD011367-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Serious adverse events, Outcome 4 Melaena.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011367.pub2/references#CD011367-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011367.pub2/media/CDSR/CD011367/image_n/nCD011367-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011367-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011367.pub2/media/CDSR/CD011367/urn:x-wiley:14651858:media:CD011367:CD011367-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011367.pub2/media/CDSR/CD011367/image_t/tCD011367-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Significant disability at discharge, Outcome 1 Significant disability at discharge." data-id="CD011367-fig-0009" src="/cdsr/doi/10.1002/14651858.CD011367.pub2/media/CDSR/CD011367/image_n/nCD011367-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Significant disability at discharge, Outcome 1 Significant disability at discharge. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011367.pub2/references#CD011367-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011367.pub2/media/CDSR/CD011367/image_n/nCD011367-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011367-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011367.pub2/media/CDSR/CD011367/urn:x-wiley:14651858:media:CD011367:CD011367-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011367.pub2/media/CDSR/CD011367/image_t/tCD011367-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Length of hospital stay, Outcome 1 Length of hospital stay: intravenous immunoglobulin (IVIG) vs standard care." data-id="CD011367-fig-0010" src="/cdsr/doi/10.1002/14651858.CD011367.pub2/media/CDSR/CD011367/image_n/nCD011367-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Length of hospital stay, Outcome 1 Length of hospital stay: intravenous immunoglobulin (IVIG) vs standard care. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011367.pub2/references#CD011367-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011367.pub2/media/CDSR/CD011367/image_n/nCD011367-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011367-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011367.pub2/media/CDSR/CD011367/urn:x-wiley:14651858:media:CD011367:CD011367-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011367.pub2/media/CDSR/CD011367/image_t/tCD011367-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Length of hospital stay, Outcome 2 Length of hospital stay IVIG vs interferon." data-id="CD011367-fig-0011" src="/cdsr/doi/10.1002/14651858.CD011367.pub2/media/CDSR/CD011367/image_n/nCD011367-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Length of hospital stay, Outcome 2 Length of hospital stay IVIG vs interferon.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011367.pub2/references#CD011367-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011367.pub2/media/CDSR/CD011367/image_n/nCD011367-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011367-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011367.pub2/media/CDSR/CD011367/urn:x-wiley:14651858:media:CD011367:CD011367-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011367.pub2/media/CDSR/CD011367/image_t/tCD011367-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Time to fever resolution, Outcome 1 Days to fever resolution: intravenous immunoglobulin (IVIG) vs standard care." data-id="CD011367-fig-0012" src="/cdsr/doi/10.1002/14651858.CD011367.pub2/media/CDSR/CD011367/image_n/nCD011367-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Time to fever resolution, Outcome 1 Days to fever resolution: intravenous immunoglobulin (IVIG) vs standard care. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011367.pub2/references#CD011367-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011367.pub2/media/CDSR/CD011367/image_n/nCD011367-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011367-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011367.pub2/media/CDSR/CD011367/urn:x-wiley:14651858:media:CD011367:CD011367-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011367.pub2/media/CDSR/CD011367/image_t/tCD011367-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Time to fever resolution, Outcome 2 Days to fever resolution IVIG vs interferon." data-id="CD011367-fig-0013" src="/cdsr/doi/10.1002/14651858.CD011367.pub2/media/CDSR/CD011367/image_n/nCD011367-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 Time to fever resolution, Outcome 2 Days to fever resolution IVIG vs interferon. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011367.pub2/references#CD011367-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011367.pub2/media/CDSR/CD011367/image_n/nCD011367-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011367-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011367.pub2/media/CDSR/CD011367/urn:x-wiley:14651858:media:CD011367:CD011367-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011367.pub2/media/CDSR/CD011367/image_t/tCD011367-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Time to stop spasms, Outcome 1 Time to stop spasms: intravenous immunoglobulin (IVIG) vs standard care." data-id="CD011367-fig-0014" src="/cdsr/doi/10.1002/14651858.CD011367.pub2/media/CDSR/CD011367/image_n/nCD011367-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 Time to stop spasms, Outcome 1 Time to stop spasms: intravenous immunoglobulin (IVIG) vs standard care. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011367.pub2/references#CD011367-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011367.pub2/media/CDSR/CD011367/image_n/nCD011367-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011367-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011367.pub2/media/CDSR/CD011367/urn:x-wiley:14651858:media:CD011367:CD011367-CMP-006-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011367.pub2/media/CDSR/CD011367/image_t/tCD011367-CMP-006-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Time to stop spasms, Outcome 2 Time to stop spasms IVIG vs interferon." data-id="CD011367-fig-0015" src="/cdsr/doi/10.1002/14651858.CD011367.pub2/media/CDSR/CD011367/image_n/nCD011367-CMP-006-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6 Time to stop spasms, Outcome 2 Time to stop spasms IVIG vs interferon.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011367.pub2/references#CD011367-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011367.pub2/media/CDSR/CD011367/image_n/nCD011367-CMP-006-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011367-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011367.pub2/media/CDSR/CD011367/urn:x-wiley:14651858:media:CD011367:CD011367-CMP-007-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011367.pub2/media/CDSR/CD011367/image_t/tCD011367-CMP-007-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Time to regain consciousness, Outcome 1 Time to regain consciousness." data-id="CD011367-fig-0016" src="/cdsr/doi/10.1002/14651858.CD011367.pub2/media/CDSR/CD011367/image_n/nCD011367-CMP-007-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7 Time to regain consciousness, Outcome 1 Time to regain consciousness.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011367.pub2/references#CD011367-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011367.pub2/media/CDSR/CD011367/image_n/nCD011367-CMP-007-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011367-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011367.pub2/media/CDSR/CD011367/urn:x-wiley:14651858:media:CD011367:CD011367-CMP-008-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011367.pub2/media/CDSR/CD011367/image_t/tCD011367-CMP-008-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Time to resolution of neuropathic symptoms, Outcome 1 Time to resolution of neuropathic symptoms: intravenous immunoglobulin (IVIG) vs standard care." data-id="CD011367-fig-0017" src="/cdsr/doi/10.1002/14651858.CD011367.pub2/media/CDSR/CD011367/image_n/nCD011367-CMP-008-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8 Time to resolution of neuropathic symptoms, Outcome 1 Time to resolution of neuropathic symptoms: intravenous immunoglobulin (IVIG) vs standard care. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011367.pub2/references#CD011367-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011367.pub2/media/CDSR/CD011367/image_n/nCD011367-CMP-008-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011367-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011367.pub2/media/CDSR/CD011367/urn:x-wiley:14651858:media:CD011367:CD011367-CMP-008-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011367.pub2/media/CDSR/CD011367/image_t/tCD011367-CMP-008-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Time to resolution of neuropathic symptoms, Outcome 2 Neuropathic symptoms IVIG vs interferon." data-id="CD011367-fig-0018" src="/cdsr/doi/10.1002/14651858.CD011367.pub2/media/CDSR/CD011367/image_n/nCD011367-CMP-008-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8 Time to resolution of neuropathic symptoms, Outcome 2 Neuropathic symptoms IVIG vs interferon. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011367.pub2/references#CD011367-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011367.pub2/media/CDSR/CD011367/image_n/nCD011367-CMP-008-02.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD011367-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Intravenous immunoglobulin with or without standard care compared with standard care alone or placebo for children with acute encephalitis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Intravenous immunoglobulin ± standard care compared with standard care alone or placebo for children with acute encephalitis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> children with acute encephalitis </p> <p><b>Settings:</b> secondary and tertiary care </p> <p><b>Intervention:</b> intravenous immunoglobulin </p> <p><b>Comparison:</b> placebo or standard care </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk (control)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk (intervention)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Standard care or placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>IVIG (± standard care)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Significant disability</b> assessed using Liverpool Outcome Score </p> <p>RR (M‐H, random‐effects analysis, 95% CI)</p> <p>Follow‐up: 3‐6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>364 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>273 per 1000</b> <br/> (80 to 945) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.75</b> </p> <p>(0.22 to 2.60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22<br/> (1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b,c,d,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear risk of detection bias and high risk of publication bias. Small sample size. Study not powered on primary outcome. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>≥ 1 serious adverse event</b> </p> <p>RR (M‐H, random‐effects analysis, 95% CI)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>91 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>91 per 1000</b> <br/> (6 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.00</b> </p> <p>(0.07 to 14.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22<br/> (1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b,c,d,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear risk of detection bias and high risk of publication bias. Small sample size. Study not powered on primary outcome. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Length of hospital stay</b> </p> <p>(MD, random‐effects analysis, 95% CI)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean length of hospital stay was 13.26</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 4.54 lower (7.47 to 1.61 lower)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>116<br/> (2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>d,f,g,h,i</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear risk of selection bias in 1 study contributing to this outcome assessment. Unclear risk of allocation concealment, performance and detection bias in both studies. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>IVIG:</b> intravenous immunoglobulin; <b>M‐H:</b> Mantel‐Haenszel; <b>MD</b> : mean difference; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Unclear risk of detection bias. </p> <p><sup>b</sup>Conflicts of interest could not be excluded. </p> <p><sup>c</sup>Study of Japanese encephalitis, therefore, results not generalisable to other forms of encephalitis. </p> <p><sup>d</sup>Small sample size in studies contributing to this outcome. </p> <p><sup>e</sup>Some predefined outcomes were not reported. </p> <p><sup>f</sup>Unclear risk of performance and detection bias in both studies contributing to this outcome. </p> <p><sup>g</sup>Unclear risk of selection bias in one study contributing to this outcome assessment. </p> <p><sup>h</sup>High proportion of variation in point estimates. </p> <p><sup>i</sup>Both studies included only children with viral encephalitis, therefore, results not generalisable to other forms of encephalitis. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Intravenous immunoglobulin with or without standard care compared with standard care alone or placebo for children with acute encephalitis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011367.pub2/full#CD011367-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011367-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Risk of bias (adverse events)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Risk of bias</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Did the researchers actively monitor for AEs or did they simply provide spontaneous reporting of AEs that arose?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Risk of bias</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Did the authors define SAEs according to an accepted international classification and report the number of SAEs?</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011367-bbs2-0001" title="ChenD‐M , LiS‐N . The clinical observation of high dose immunoglobulin for children viral encephalitis. Chinese Journal of Primary Medicine and Pharmacy2006;13(5):816‐7. ">Chen 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Information not provided.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Information not provided.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011367-bbs2-0002" title="RayamajhiA , NightingaleS , BhattaNK , SinghR , LedgerE , BistaKP , et al. A preliminary randomized double blind placebo‐controlled trial of intravenous immunoglobulin for Japanese encephalitis in Nepal. PloS One2015;10(4):e0122608. ">Rayamajhi 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The authors reported that participants were monitored for AEs from first day of commencing treatment until death or discharge </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AEs graded using WHO recommendations and reported to an independent data safety monitoring committee. Information recorded on standardised proformas. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011367-bbs2-0003" title="WuH , WanZ , LiuL , QiuL , XiulingD . Comparison of the clinical efficacy of immunoglobulin and interferon in the treatment of hand foot and mouth disease complicated with viral encephalitis. Chinese Journal of Primary Medicine and Pharmacy2014;21:3127‐8. ">Wu 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Information not provided.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Information not provided.</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>AE: adverse events; SAE: serious adverse events; WHO: World Health Organisation.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Risk of bias (adverse events)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011367.pub2/full#CD011367-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011367-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Significant disability at six months</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Significant disability at 3‐6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.22, 2.60]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Significant disability at six months</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011367.pub2/references#CD011367-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011367-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Serious adverse events</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 ≥ 1 serious adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.07, 14.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.5 [0.05, 4.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Hypotension <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.07, 14.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Melaena <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.07, 14.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Serious adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011367.pub2/references#CD011367-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011367-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Significant disability at discharge</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Significant disability at discharge <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.60, 1.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Significant disability at discharge</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011367.pub2/references#CD011367-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011367-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Length of hospital stay</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Length of hospital stay: intravenous immunoglobulin (IVIG) vs standard care <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.54 [‐7.47, ‐1.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Length of hospital stay IVIG vs interferon <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.57 [‐0.99, ‐0.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Length of hospital stay</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011367.pub2/references#CD011367-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011367-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Time to fever resolution</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Days to fever resolution: intravenous immunoglobulin (IVIG) vs standard care <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.97 [‐1.25, ‐0.69]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Days to fever resolution IVIG vs interferon <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.27 [‐0.42, ‐0.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Time to fever resolution</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011367.pub2/references#CD011367-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011367-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Time to stop spasms</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Time to stop spasms: intravenous immunoglobulin (IVIG) vs standard care <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.49 [‐1.97, ‐1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Time to stop spasms IVIG vs interferon <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.17 [‐0.34, 0.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Time to stop spasms</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011367.pub2/references#CD011367-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011367-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Time to regain consciousness</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Time to regain consciousness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.10 [‐1.48, ‐0.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Time to regain consciousness</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011367.pub2/references#CD011367-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011367-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Time to resolution of neuropathic symptoms</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Time to resolution of neuropathic symptoms: intravenous immunoglobulin (IVIG) vs standard care <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.20 [‐3.34, ‐3.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Neuropathic symptoms IVIG vs interferon <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.49 [‐0.70, ‐0.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Time to resolution of neuropathic symptoms</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011367.pub2/references#CD011367-tbl-0010">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD011367.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD011367-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD011367-note-0004">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD011367-note-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD011367-note-0003">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD011367-note-0002">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD011367-note-0005">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011367\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011367\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011367\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011367\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011367\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011367\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011367\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011367\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011367\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011367\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011367\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011367\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011367\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011367\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011367\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011367\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011367\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011367\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=6nHUP32m&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011367.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011367.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD011367.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD011367.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011367.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740717732505"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011367.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740717732509"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011367.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dbf1f19f4936b',t:'MTc0MDcxNzczMy4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 